COMPOSITION CONTAINING AMINE AND AMINE-RELATED DERIVATIVES OF BENZOIC ACID AND USES THEREFOR INCLUDING TREATING INFLAMMATORY DISEASES

Abstract: The invention is drawn to a novel composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases.

Description: Composition containing amine and amine-related derivatives of benzoic acid and uses there including treating inflammatory diseases I . SUMMARY OF THE INVENTION The present invention is directed to the use of composi¬ tions consisting of amine and amine-related benzoic acid deriv¬ ative primary agents capable of covalently binding carbonyl substances and co-agents consisting of antioxidants, free radical trapping substances, vitamins and vitamin-related sub¬ stances, for use in the treatment of symptoms of chronic inflam¬ matory disorders, said disorders featuring oxidative free radi¬ cal reactions, lipid peroxidation and generation of carbonyl compounds as aspects of their etiologies. The invention relates to the use of a composition compris¬ ing a therapeutically effective amount of a primary agent and at least one co-agent, said primary agent comprising a water solu¬ ble, low molecular weight primary amine or amine-related deriv¬ ative of benzoic acid in the molecular weight range of 100 to 1,400, for use in the treatment of symptoms of chronic inflam¬ matory disorders featuring pathology based in part on increased lipid peroxidation, wherein said primary and co-agent combina¬ tion produces an anti-inflammatory and analgesic effect. In such a preferred embodiment of the use of a composition comprising a therapeutically effective amount of a primary agent and at least one co-agent for treatment of the symptomology of a chronic inflammatory disease, the chronic inflammatory disease is characterized in part by the deterioration of intracellular and extracellular structures and is characterized by the ■ spurious pathological chemical covalent bond crosslinking of said structures, formation of pathological addition products of said structures, or chemical cleavage products of said struc¬ tures, said deterioration resulting from reaction of inflamma¬ tion site structures in the human with disease-induced carbonyl- containing aliphatic and aromatic hydrocarbons resulting from increased lipid peroxidation associated with chronic inflamma¬ tion. In a preferred embodiment of this aspect of the invention, the primary agent has at least one primary amino group or amine- related group thereon for reaction with lipid peroxidation product carbonyl groups to decrease the deterioration of said intracellular and extracellular structures and to decrease the spurious pathological chemical crosslinking, other derivation or cleavage of said structures by permitting a therapeutically effective amount of said primary agent to effectively compote with and covalcntly bind to said disease-induced carbonyl- containing lipid peroxidation products. In a preferred embodiment, the use of the primary agent is additionally characterized in that it does not interact with normal cell metabolism of said human or docs so in a non- cytotoxic manner, and the primary agent is readily absorbed by the kidney tissue of said human and excreted in the urine of said human without nephrotoxic conseguences . In a preferred embodiment, the use of a water soluble primary agent of molecular weight in the range of 100 to 1,400 is selected from the group consisting of the free acid forms, salts, benzene ring isomers, amide derivatives, carboxylic acid ester derivatives and analogous non-aromatic benzene ring derivatives of the group consisting of: oalkyl group having carbons including ocarbon isomers or hydroxylatod vatives thereof -NHC(=NH)NH, -(CH 2 ) n NHC(=NH)NH, where n = 1-10 -C(=NH)-NH (continued ; CH,) n -CH=NC(=NH)NH , where n = 1-10 • NHC (=NH) NHNH,, ■• (CH ? ) n NHC{=NH ' )NHNH , where n - 1-10 - (CH,) n -CH=NC(=NH)NHNH , where n - 1-10 -NHNHC(=NH)NH, -(CH ? ) π --NHNHC(-NH)NH, where n = 1-10 - (CH,) n -CH=N- NHC(^NH)NH where n = 1-10 R, = -NH -amm 1 oalkyl group (1-10 carbons) on -NHC(=NH)NHNH ? -(CH ? ) nNHC(=NH)NHNH, whore n = 1-10 -(CH j ) n -CH=NC(=NH)NHNH 2 where n = 1-10 -NHNHC(=NH)NH ? -(CH,) n -NHNHC(=NH)NH, where n = 1-10 - (CH 2 ) π -CH=N-NHC(=NH)NH , where n = 1-10 R = -NH 2 -OH ' -0-CH 3 -0-R ' with alkyloxy group R 1 having 2-10 carbons including hydrocarbon isomers and/or hydroxylated derivatives thereof -αminoalkyl group (1-10 carbon ) including hydrocarbon isomers and/or hydroxylated derivatives thereof -SO ^H -CH ? - ( CH ,) n CH 3 wherc n = 1- 10 including hydrocarbon ( cont inued ) isomers and/or hydroxylated derivatives thereof -10 of up f - (CH,) -CH=NC(=NH)NH where n = 1-10 -NHC(=NH)NHNH, -(CH -) n NHC( =NH)NHNH ? where n = 1-10 - (CH 2 ) n -CH=NC(==NH)NHNH - where n = 1-10 -MHNHC(=NH)NH 2 -(CH 2 ) n -NHNHC ( =NH)NH 2 where n = 1-10 -(CH 2 ) -CH=N-NHC(=NH)NH 2 where n = 1-10 R 2 = -NH, -H " -OH -0-CH 3 -0-R3 where alkyloxy group R 3 has 2-10 carbons including hydrocarbon isomers αnd/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof including hydrocarbon isomers and/or hydroxylated derivatives thereof R' = -H R" = -H -CH, -OH " . for controlling the symptoms of disorders selected from the group consisting of chronic gingivitis, chronic poriodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus , autoimmune vasculitis, αsbestosis, silicosis, chronic obstruc¬ tive pulmonary disease, Lyme disease, inflammatory myopathics, status epilopticus, inflammatory neuropathies, myasthenia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and reparfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. In a preferred embodiment, the primary agent is used in a dosage in the range of one gram/day to 20 grams/day. In a preferred embodiment, the primary agent is adminis¬ tered orally. In a preferred embodiment, the primary agent is adminis¬ tered intravenously. In a preferred embodiment , the co-agent is a non-absorbable polyamine substance or non-absorbable polyamine-related sub¬ stance, a therapeutically effective amount of said co-agent acting to covalently bind to and sequester dietary carbonyl- containing products. In a preferred embodiment , the co-agent is a non-absorbable polyamine substance or non-absorbable polyamine-related sub¬ stance selected from the group consisting of: a. naturally occurring polysaccharides having beta-1,2, bota- 1,3, beta-1,4 and/or bcta-1,6 linkages containing aminosugars including the chitin class of biopolymers having the general structure of poly-beta-(l-»4)-N-acetγl-D-glucosamine, and bear¬ ing at least one free primary αmine group; b. deacetylated naturally occurring polysaccharides , having at least one N-acetylatεd residue, including chitosan, deacetylated chondroitin sulfate, or deacetylated hyaluronic acid; c. chemically aminated polysaccharides selected from the group consisting of: aminodeoxy polysaccharides such as 2-amino-2-deαxy- cellulos ; aminoalkyl-, amino(hydroxyalkyl )- , aminoalkyl-ethcr- , and αmino( hydroxyalkyl ) -other- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates selected from the group consisting of H2 N-(CH2) n -[carbohydrate] where n = 1-10, including alkyl isomers ; H 2 N-(CH 2 ) B -CHOH-(CH 2 ) n -[carbohydrate] , where m = 0-10 and n = 0-10; H 2 N-(CH 2 ) n -0-[carbohydrate] where n = 1-10; H 2 N-(CH 2 ) ro -CHOH-(CH2) n -0-[carbohydrate] where m = 0-10 and n = 0-10; aminobcnzy]- .τrivativcs of cellulose, chitin or other naturally occurring non-digestible carbohydrates selected from the group consisting of H 2 N-C 6 H 4 -(CH 2 ) n -[carbohydrate] , H j N-CH 2 -C 6 H,-(CH 2 ) n -[carbohydrate] , H j N-C g H-(CH 2 ) n -0-[carbohydrate] where n = 0 - 10, and H 2 carbohydrate] where m = 0-10 and n = 0-10, including p- , o- and m-benzene ring amino- isomors, aminomethyl- isomers and alkyl group isomers thereof ; guanidine and aminoguanidinc derivatives of cellulose, chitin or other naturally occurring non-absorbable carbo¬ hydrates selected from the group consisting of: H2N-C(=NH)-[carbohydrate] ; H^ϊ-C(=NH)-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; H2N-C(=NH)-0-(CH 2 ) n -[carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers, ether linkage isomers and hydrox¬ ylated derivatives thereof; H2N-C(=NH)-NH-[carbohydrate] ; H^ϊ-C(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers and hydroxylated derivatives thereof ; carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, .ether linkage isomers and hydroxylated derivatives thereof; H2ϊ-C(=NH)-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; carbohydrate] , where n= 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H j N-NHC(=NH)-NH-[carbohydrate] ; H^f-NHC(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H; -NHC(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H ϊ-C(=NH)-NH-NH-[carbohydrate] ; H2N-C(=NH)-NH-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; H2 -C(=NH)-NH-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^J-C(=NH)-NH-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-NH-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; d. primary amine, aminoguanidine and guanidinc derivatives of sucrose polyesters having one or more carbonyl trapping func¬ tional group per molecule wherein each carbonyl trapping functional group is in the omega-, omoga-1 or other isomeric position within the fatty acyl chains, wherein each fatty acyl chain may have from 3 to 26 carbons, from one to five nitrogen functional groups and from one to 24 hydroxyl groups; e. synthetic polysaccharides consisting partly or entirely of aminosugars bound by beta-1,2, bota-1,3, botα-1,4 and/or bota- 1,6 linkages; f. mixed polysaccharidc polymeric derivatives wherin primary amino, aminoalkyl (one to ten carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per αlkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ten carbons per alkyl group) , aminoalkyl- guanidinyl (one to ton carbons per alkyl group) , guanidine, aminobenzene and/or aminoalkylbcnzcnc (one to ten carbons per αlkyl group) functional groups are covalently attached to matrices such as cpi-chlorohydrin copolymers of cellulose or chitin and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups; and g. non-polysaccharido polymeric derivatives wherein primary amine, aminoalkyl (one to ten carbons per alkyl group), aminohy- droxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ton carbons per alkyl group), aminoalkyl- guanidinyl (one to ten carbons per alkyl group) , guanidine, aminobenzene and/or aminoalkylbonzone (one to ton carbons per alkyl group) functional groups are covalently attached to a synthetic non-digestible polymer selected from the group consisting of polystyrene, styrene-divinylbcnzenc copolymer, polyvinyl alcohol and crosslinkod derivatives thereof, and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups, for controlling the symptoms of disorders selected from the group consisting of chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus crythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstruc¬ tive pulmonary disease, Lyme disease, inflammatory myopathies , status αpilopticus, inflammatory neuropathies, myasthonia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and repcrfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. In a preferred embodiment, the co-agent is a non-αbsorbable polyamine substance or non-absorbable polyamine-related sub¬ stance which is in a microfibrillatod form or microcrystαllino form having enhanced surface area, increased porosity, increased water retention capacity and enhanced chemical accessibility. In a preferred embodiment, the therapeutically effective amount of said co-agent is a dosage in the range of one gram/day to 40 grams/day. In a preferred embodiment, the therapeutically effective amount of said non-absorbable polyamine co-agent or non- absorbable polyamine-related co-agent is administered orally. In another preferred embodiment, the use additionally comprises use of at least one co-agent selected from the group consisting of antioxidants and free radical trapping compounds, chemicals having indirect antioxidant properties, suspending reagents, vitamins and derivatives thereof, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulfhydryl containing chemicals, for controlling the symptoms of disorders selected from the group consisting of chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitiε, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbostosis, silicosis, chronic obstruc¬ tive pulmonary disease, ymc disease, inflammatory myopathics, status epilepticus, inflammatory neuropathies, myasthonia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and repcrfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. In another preferred embodiment , one or more co-agent se¬ lected from the group consisting of antioxidants and free radi¬ cal trapping compounds, chemicals having indirect antioxidant properties, suspending reagents, vitamins and derivatives thereof, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulf¬ hydryl containing chemicals is administered orally. In another preferred embodiment , one or more co-agent s — looted from the group consisting of antioxidants and free radi¬ cal trapping compounds, chemicals having indirect antioxidant properties, suspending reagents, vitamins and derivatives thereof, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulfhydryl containing chemicals is administered intravenously. In another aspect of this invention, the invention relates to the use of a composition for treating a mammal suffering from a chronic inflammatory disorder featuring pathology which in¬ cludes in part increased lipid peroxidation comprising orally or intravenously administering a therapeutically effective amount of a primary agent in combination with at least one co-agent, wherein said mammalian disorder is selected from a group con¬ sisting of arthritis, inflammatory site edema, acute central nervous system trauma, stroke and myocardial infarction, wherein the primary therapeutic agent is selected from the group con¬ sisting of primary amino and amine-related benzoic acid deriva¬ tives which arc water soluble and of molecular weight 100 to 1,400 as defined above, wherein the primary agent acts by covalently binding to and sequestering carbonyl compounds in said mammal which result from increased lipid peroxidation, and wherein said primary agent is administered with at least one co- agent selected from the group consisting of non-αbsorbable polyamine substances, non-absorbable polyamine-related sub¬ stances, antioxidants and free radical trapping compounds, chemicals having indirect antioxidant properties, suspending reagents, vitamins and derivatives thereof, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulfhydryl containing chemicals as defined above. In a preferred embodiment, the primary agent of this invention is used to treat a mammal in a dosage in the range of 10 g/kg/day to 1.0 gm/kg/day. In a preferred embodiment, the non-absorbable polyamine substance or non-absorbable polyamine-related substance as defined above is used to treat ε> mamπ -J in a dosage in the range of 10 mg/kg/dαy to 1.0 gm/kg/dαy. In another aspect of the invention, the invention relates to a pharmaceu ical composition for use in the treatment of the symptoms of disorders selected from the groxip consisting of: chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumu¬ lative trauma disorders, systemic lupus erythematosus, auto¬ immune vasculitis, asbostosis, silicosis, chronic obstructive pulmonary disease , Ly e d srase , inflammatory yopathies , status epilepticus, inflammatory neuropathies, myasthenia gravis, multiple sclerosis, a ; well as lessening of inflammatory site edema, and treatment of post-event ischemia and repcrfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction, the composition comprising one or more water soluble, low molecular weight primary agent (100 to 1,400 range of molecular weights) selected from the free acid forms, salts, benzene ring isomers, amide derivatives, carboxylic acid ester derivatives and analogous non-aromatic benzene ring derivatives of the group consi ting o : oalkyl group having carbons including ocarbon isomers or hydroxylated vatives thereof -NHC(=NH)NH 2 -(CH 2 ) n NHC(=NH)NH 2 where n = 1-10 -NHC(=NH)NHNH, -(CH 2 ) n NHC(=NH)NHNH 2 where n = 1-10 - (CH 2 ) n -CH=NC(=NH)NHNH, where n = 1-10 -NHNHC( =NH)NH -(CH 2 ) n -NHNHC(=NH)NH, where n = 1-10 - (CH,) n -CH=N-NHC(=NH)NH , where n = 1-10 R, -= -NH, -aminoalkyl group (1-10 carbons) including hydrocarbon -NHC(=NH)NHNH_, -(CH,) n NHC(^NH)NHNH, wher n = 1-10 - (CH 2 ) n -CH=NC(=NH)NHNH ; where n = 1-10 -NHNHC(=NH)NH, -(CH,) n -NHNHC(=NH)NH ? whore n = 1-10 (CH 2 ) n -CH=N--NHC(=^NH)NH where n = 1-10 R, = -NH, -OH with αlkyloxy group R' having 2- 10 carbons including hydrocarbon isomers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof -SO ji -CH 3 - (CH,) n CH 3 where n = 1-10 including hydrocarbon isomers and/or hydroxylated derivatives thereof = 0- 10 s of roup eof ( continued) -(CH,) n -CH=NC(-NH)NH , where n = 1-10 -NHC(=NH)NHNH - -(CH,) η NHC(=NH)NHNH : where n = 1-10 - (CH,) n -CH=NC(=NH)NHNH, where n = 1-10 -NHNHC(=NH)NH, -(CH,) n -NHNHC{=NH)NH-, whore n = 1-10 -(CH,) n -CH=N-NHC(=NH)NH, where n = 1-10 y rocar on somers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof -SO j H -CH 3 -(CH 2 ) r pH 3 wherc n = 1-10 including hydrocarbon isomers and/or hydroxylated derivatives thereof R 1 = -H -CH 3 -OH R" = -H -CH 3 -OH, in a dosage range of from one gram/day to 20 grams/day, in association with α pharmaceutically acceptable carrier thereof. In another preferred embodiment, this pharmaceutical com¬ position comprises the use of at least one co-agent. In another aspect of this invention, the invention relates to a pharmaceutical composition for use in the treatment of the symptoms of disorders selected from the group consisting of: chronic gingivitis, chronic periodontitis, chronic auto¬ immune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstruc¬ tive pulmonary disease, Lyme disease, inflammatory myopathies, status epilepticus, inflammatory neuropathies, yasthenia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and repcrfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction, the composition comprising one or more non-absorbable poly¬ amine co-agent or non-absorbable polyamine-related co-agent selected from the group consisting of: a. naturally occurring polysaccharides having bcta-1,2, beta- 1,3, beta-1,4 and/or beta-1,6 linkages containing aminosugars including the chitin class of biopolymers having the general structure of poly-beta-(l→4)-N-acetγl-D-glucosaminc, and bear¬ ing at least one free primary amine group; b. deacetylated naturally occurring polysaccharides, having at least one N-acetylated residue, including chitosan, deacetylated chondroitin sulfate, or deacetylated hyaluronic acid; c. chemically aminated polysaccharides selected from the group consisting of: aminodeoxy polysaccharides such as 2-amino-2-deoxy- cellulose; aminoalkyl-, amino(hydroxyalkyl )- , aminoalkyl-cthcr-, and amino(hydroxyalkyl) -ether- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates selected from the group consisting of H 2 N-(CH2) n -[carbohydrate] where n = 1-10, including alkyl isomers ; H j N-(CH 2 ) a -CH0H-(CH 2 ) n -[carbohydrate] , where m = 0-10 and n = 0-10; H2N-(CH 2 ) n ~0-[carbohydrate] where n = 1-10; H 2 N-(CH 2 ) 0 -CHOH-(CH 2 ) n -0-tcarbohydrate] where m = 0-10 and n = 0-10; aminobenzyl- derivatives of cellulose, chitin or other naturally occurring non-digestible carbohydrates selected from the group consisting of H N-C 6 H r (CH 2 ) n -[carbohydrate] , H 2 N-CH 2 -C 6 H 4 -(CH 2 ) n -[carbohydrate] , H 2 N-C 8 H 4 -(CH 2 ) n -0-[carbohydrate] where n = 0 - 10, and H 2 N-C 6 H 4 -(CH2) (n -CHOH-(CH 2 ) n -0-tcarbohydrate] where m = 0-10 and n = 0-10, including p- , o- and m-bcnzcnc ring amino- isomors, αminomothyl- isomers and alkyl group isomers thereof ; guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring non-absorbable carbohydrates selected from the group consisting of : H j N-C(=NH)-[carbohydrate] ; H2N-C(=NH)-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; HH-C(=NH)-0-(CH 2 ) n -1carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers, ether linkage isomers and hydrox¬ ylated derivatives thereof; H Ϊ-C(=NH)-NH-[carbohydrate] ; H2N-C(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^Ϊ-C(=NH)-N=CH-{CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n= 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof ; H^J-NHC(=NH)-NH-[carbohydrate] ; H,N-NHC(=NH)-NH-(CH2) „-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n - 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H 2 N-NHC(=NH)-N=CH-(CH 2 ) n -[carbohydrate] , where n - 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; H2N-NHC(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = .1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^Ϊ-C(=NH)-NH-NH-[carbohydrate] ; H^ϊ-C(=NH)-NH-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H^I-C(=NH)-NH-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-NH-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H^-C(=NH)-NH-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; d. primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters having one or more carbonyl trapping func¬ tional group per molecule wherein each carbonyl trapping func¬ tional group is in the omega-, omoga-1 or other isomeric position within the fatty acyl chains, wherein each fatty acyl chain may have from 3 to 26 carbons, from one to five nitrogen functional groups and from one to 24 hydroxyl groups; o. synthetic polysaccharides consisting partly or entirely of aminosugars bound by bcta-1,2, beta-1,3, beta-1,4 and/or bcta- 1,6 linkages; f . mixed polysaccharidc polymeric derivatives wherein primary amine, aminoalkyl (one to ton carbons per αlkyl group), αmino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per αlkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ten carbons per alkyl group) , aminoalkyl- guanidinyl (one to ton carbons per αlkyl group), guanidine, aminobenzene and/or aminoalkylbenzcne (one to ten carbons per alkyl group) functional groups are covalently attached to matrices such as cpi-chlorohydrin copolymers of cellulose or chitin and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups; and g. non-polysaccharidc polymeric derivatives wherein primary αmine, aminoalkyl (one to ton carbons per alkyl group), αminohy- droxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group), aminoguanidine, αminoguani- dinylalkyl (one to ten carbons per alkyl group), aminoalkyl- guanidinyl (one to ten carbons per αlkyl group), guanidine, aminobenzene and/or aminoalkylbcnzenc (one to ten carbons per alkyl group) functional groups are covalently attached to a synthetic non-digestible polymer selected from the group con¬ sisting of polystyrene, styrene-divinylbenzone copolymer, polyvinyl alcohol and crosslinked derivatives thereof, and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups, in a dosage range of from one gram/day to 40 grams/day, in a microfibrillated form or microcrystallino form having enhanced surface area, increased porosity, increased water retention capacity and enhanced chemical accessibility, and in associ¬ ation with a pharmaceutically acceptable carrier thereof. In another aspect of this invention, the invention relates to a pharmaceutical composition comprising at least one co-agent selected from the group consisting of antioxidants and free radical trapping compounds, chemicals having indirect anti¬ oxidant properties, suspending reagents, vitamins, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulfhydryl containing chemicals. BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the clinical treatment of chronic inflammatory diseases, including chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, iloitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstructive pulmonary disease, Lymc disease, inflamma¬ tory myopathies, status epilepticus, inflammatory neuropathies, myasthcnia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and rcperfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. No pharmacological treatment of comprehensive effectiveness is currently available for any of the chronic inflammatory dis¬ orders or ctiologically related symptomology discussed herein. 2. Description of Prior Art The logic and potential value, even syncrgisti c value , of using two or more therapeutic agents in combination has been recog¬ nized previously (Ghose and coworkers, 1983; Flood and cowork- ers, 1988; Goldstein and coworkers, 1990, pg. 102; Rinnε, 1991) . For example, Brooks and Schwarzcr (1991) noted that: Long term (five years or more) studies of SAARDs [slow acting antirheumatic drugs] in rheumatoid arthritis suggest that less than 50* of patients are taking gold, D-pcnicillamine, sulphasalazinc, or anti-malarial drugs five years after the start.11-15 Patients whose disease was initially controlled by these agents ceased taking the drugs because of either the development of side effects or a flare in disease activity, despite contin¬ uation of the treatment... ...As the pathogenetic processes of rheumatoid arthritis are so complex it is extremely unlikely that any single agent will block all the pathways leading to joint de¬ struction. It might, therefore, bo reasonable to con¬ sider using combinations of drugs, cither simultaneously or cyclically... Numerous prior art publications disclose that vitamin E func¬ tions physiologically as α lipid-soluble antioxidant free radical trapping agent. Prior art publications describe methionine as a water-soluble agent, an essential amino acid, an antioxidant and α free radical trapping agent. Primary agents of this invention are selected from the group consisting of p-αminobenzoic cid (PABA) and derivatives thereof. p-Aminobenzoic acid is known as a water-soluble B vitamin, and several published studies have presented evidence to the effect that PABA functions, in part, as a weak anti¬ oxidant and a weak free radical trapping agent (Maksimov and Rcbachuk, 1985, Table 2; Pryor and coworkers, 1976, pg. 201) . In so far as benzoic acid or derivatives thereof have been re¬ cognized as antioxidants or free radical trapping agents, their mechanism of. action is understood to consist of hydroxyl radical trapping by the benzene ring (Grootveld and Halliwell, 1988; Halliwell and Guttoridgo, 1985, pp. 105 and 130; Richmond and coworkers, 1981; Repine and coworkers, 1979, pg. 1642) . This has been explicitly demonstrated for PABA (Nakkon, 1964, pp. 446, 448, 454-457; Nakkcn and Pihl , 1966, pp. 21, 22, 24, 25 and 28) . Likewise, mannitol is recognized as an antioxidant based on its ability to scavenge hydroxyl radicals (Halliwell and Gutteridge, 1985, pp. 97 and 105), and a similar mechanism of action is recognized for dimethyl sulfoxidc (Halliwell and Gutteridge, 1985, pg. 147) and methionine (Del Maestro, 1980, 164-165) . Clinical use of the drug sulfasalazinc (SAZ) represents a well documented example of the use of a benzoic acid derivative as a trapping agent for the hydroxyl radical and other free radicals in the treatment of a chronic inflammatory disease. In the colon SAZ undergoes reductive cleavage to liberate 5-amino- salicylic acid (5-ASA), which is the therapeutically active agent. Ahnfclt-Ronne and coworkers (1990) have presented research findings which docomont the use of sulf salazinc for successful treatment of chronic inflamatory bowel disease (CIBD) , also known as ulcorativo colitis. Summarizing heir work, these investigators noted: The present results thus lead us to propose the following mechanism of action of SAZ in the treat¬ ment of CIBD. After cleavage of SAZ by reductive processes in the colon, 5-ASA is released in high concentrations. 5-Aminosalicylic acid is a highly effective scavenger of free radicals and interacts with hydroxyl and other radicals to form a novel major metabolite of 5-ASA, Ml and several minor metabolites. In this reaction, 5-ASA breaks the free radical chain reaction. The cytotoxic and tissue-destructive effects of this otherwise per¬ petuating process arc thereby gradually aborted. This action of 5-ASA manifests itself clinically as an antiinflammatory effect, and the proposed mechanism of action implies that free radicals arc of major importance in producing the clinical signs of chronic inflammation... (pgs. 1168-1169) Yet several points servo to distinguish this previous work on SAZ from the present invention. Based on high performance liquid chromatographic elution times and ultraviolet spectra data, Ahnfclt-Ronne compared their _in_ vivo 5-ASA metabolic products to products observed after in vitro hydroxylation of 5- ASA . by the Fenton reaction and tentatively identified 5-ASA metabolites as being hydroxylated derivatives. Yet they never explicitly identified the chemical structures of the disease- specific metabolic products they observed. Nor was there any attempt on their part to look for evidence of in vivo trapping of carbonyl products. Dull and coworkers (1987, pg. 2469) used mass spectrometry to definitively identify two of the several hydroxylation/oxidative doamination products which result from in vitro incubation of 5-ASA with activated human mononuclcar cells. They identified these products as gentisic acid (2,5- dihydroxybenzoic acid) and salicylic acid (2-hydroxy benzoic acid), while five other 5-ASA metabolic products remained unidentified (pg. 2470) . There also was a curious methodological oversight in the study of Ahnfelt-Ronnc and coworkers. They included several rheuma¬ toid arthritis (RA) patients in their SAZ study as one of their control groups and reported, in part: ...The presence of Ml and other Fenton reaction products of 5-ASA in extracts of feecs samples from CIBD patients treated with SAZ is clearly demon¬ strated. In contrast, none of the metabolites M1-M6 were detected in stool extracts from SAZ-troαtod RA patients. These extracts contained 5-ASA, sulfa- pyridino, and N-acotyl-5-ASA in the normal range for SAZ-trcatcd patients... (p . 1165) This represents a misconceived use of a control group, as CIBD is a chronic inflammatory disorder of the intestinal tract, while RA is not. Ahnfεlt-Ronno and coworkers failed to examine urine or blood samples from their RA patients for evidence of metabolites M1-M6, which is whore one would logically expect to find such metabolites. Ahnfelt-Ronne and colleagues, like earlier investigators, never recognized the possibility of using α therapeutic agent to scavenge carbonyl products of inflammation. Hence they never recognized the possibility of intentionally using a composition consisting of a primary agent which sequesters carbonyl products in combination with co-agents that have known antioxidant properties. Further distinctions should be noted between the present inven¬ tion and previously recognized clinical use of SAZ in that SAZ releases sulfapyridinc, a somewhat toxic substance, into into the body (Peppercorn, 1984, pgs . 377-379 and 383), while the present invention docs not, and use of sulfasalazinc depends on intestinal bacteria for activation of the drug, while the primary agents of the present invention do not. Besides use in treatment of CIBD and iloitis (Budavari and coworkers, 1989, pg. 1412), SAZ has been recognized , at least at the experimental level, for treatment of radiation bowel disease, sclcrodcrma, dermatitis horpetiformis and rheumatoid arthritis (Peppercorn, 1984, pgs 380-381) . Other examples of amine drugs recognized as having anti-inflam¬ matory properties include para-substituted N-bonzenesulfonyl derivatives of anthrilic acid (Borne and coworkers, 1974), 4- αmino benzoic acid anilides (Thiele, 1971; Deutsche Gold- und Silber-Schcideanstalt vorm. Rocssler, 1972) and Tinoridinc (Shimada and Yasuda, 1979) . The chemical structures of these agents lie beyond the present invention, they arc not presently recognized as carbonyl sequestering agents, and they have not been used in multiple ingredient compositions analogous to those of the present invention. Several drug products containing PABA have been marketed for human use in the United States. However, none include the inventive concept or compositions claimed herein. Potassium p- aminobonzoate has been marketed as Potaba (R) in the pure form as an antifibrotic, i.e., skin softening, agent (Drug Infor¬ mation for the Health Care Professional, 8th od., 1988, pgs. 111-113) . As such it has been recognized for treatment of Pcyronic's disease; diffuse systemic sclerosis; morphca and linear scleroderma; and dormatomyositis . For such purposes, Potaba (R) is taken orally in average doses of 12 grams/day for up to two years, although human use of 15 - 20 grams/day is recognized. As an ingredient in analgesic tablets, PABA has been marketed for domestic human use (300 mg/tablot) in Pabirin (R) buffered tablets (with aspirin) , in Pabalate (R) tablets (with sodium salicylato) and in Pabalatc-SF (R) tablets (with potassium salicylate) , as described in Physicians' Desk Reference (Huff, 1980, pgs. 849, with aspirin and 1430, with salicylates ) . Five percent PABA in a cream base has also been marketed as a sunscreen product (Physicians' Desk Reference, Huff, 1980, pg. 849) . In its summary on systemic use of PABA the Drug Information for the Health Care Professional text (8th cd. , 1988, pg. Ill) presented the following statement (reproduced herein its entirety) : Mechanism of action: The mechanism by which aminobenzoate potassium exerts its αntifibrotic effect is not known. It has been postulated that fibrosis results from an im¬ balance of serotonin and monoaminc oxidaso (MAO) mechan¬ isms at the tissue level. Fibrosis is believed to occur when an excessive serotonin effect is sustained over α period of time. This could be the result of too much serotonin or too little MAO activity. Aminobenzoate potassium increases oxygen utilization at the tissue level. It has boon suggested that this increased oxygon utilization could enhance the degradation of serotonin by enhancing MAO activity or other activities that decrease the tissue concentration of serotonin. In its summary on systemic use of potassium p-aminobonzoate the Physician's Desk Reference (Dowd, 1993, pg. 1103) presented the following statement (reproduced herein its entirety): INDICATIONS Based on a review of this drug by the National Acad¬ emy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows : 'Possibly' effective: Potassium aminobenzoate is possi¬ bly effective in the treatment of scleroderma, dermato- myositis, orphea, linear scleroderma, pemphigus, and Peyronie's disease. Final classification of the less-than-cffcctivc indi¬ cations requires further investigation. ADVANTAGES POTABA offers a means of treatment of serious and often chronic entities involving fibrosis and nonsuppurativo inflammation. PHARMACOLOGY P-Aminobcnzoatc is considered a member of the vitamin B complex. Small amounts arc found in cereal, eggs, milk and moats. Detectable amounts are normally pre¬ sent in human blood, spinal fluid, urine, and sweat. PABA is a component of several biologically important systems, and it participates in a number of funda¬ mental biological processes. It has been suggested that the antifibrosis action of POTABA is due to its mediation of increased oxygon uptake at the tissue level. Fibrosis is believed to occur from cither too much serotonin or too little monoamine oxidaso activity over a period of time. Monoamine oxidasc requires an adequate supply of oxygon to function properly. By increasing oxygen supply at the tissue level POTABA may enhance MAO activity and prevent or bring about re¬ gression of fibrosis. This inventor sees no relationship of such comments to the pre¬ sent invention. In particular, the comments noted above clearly do not recognize the potential use of PABA and derivatives thereof as carbonyl trapping agents, that is, as agents which may generally inhibit chronic inflammatory disorders by virtue of thoir ability to chemically bind to and sequester aldehyde and ketone products of lipid peroxidation which result from and contribute to the continuation of chronic inflammatory disor¬ ders. Hence the clinical applications of PABA and derivatives thereof claimed in the present invention are regarded by the inventor as new and novel . Certain amine agents have recognized antioxidant properties. These include N,N' -di-(sec-butyl )-p-phenylenediaminc (Scott, 1965, pg. 120), aniline and aniline N-subsyituted agents (Scott, 1965, pg. 125). In the present invention focus is placed on primary αmine agents, as such agents are known to covalently react with carbonyl agents to yield Schiff base-type products (Fεonoy and coworkers, 1975, pg. 141) . By contrast, N-sub- stitution with hydrocarbon functional groups tends to increase αmine antioxidant activity (Scott, 1965, pgs. 125 and 148) . These arc two distinct chemical phenomena. The antioxidant property of amines depends on their ability to act as electron donors to alkoxy or αlkylporoxy radicals (Scott, 1965; pgs. 127, 145 and 158) . The carbonyl trapping property of amines depends on their ability to form Schiff base-type addition products. Vitamin C (ascorbic acid) is widely recognized as a water-solu¬ ble antioxidant vitamin. However, numerous published studios which have appeared since 1980 document that vitamin C also can act physiologically as a pro-oxidant (Gutteridge and Wilkins, 1982) , an agent which stimulates lipid peroxidation (Chojkicr and coworkers, 1989, pgs. 16957 and 16961) , and that it is a strong protein glycosylating agent (Ortwerth and Olcscn, 1988, pgs. 12, 14, 16, 18 and 20) . Thus, for example, in vitro studies have documented the ability of vitamin C to accelerate the process of cataract formation (Slight and coworkers, 1990, pgs. 369-373) . In addition, some evidence suggests that ascor¬ bic acid may act as a factor which stimulates certain reactions which are characteristic of inflammatory diseases. For example, the presence of ascorbic acid in the synovial fluid of the arthritic joint may contribute to degradation of hyaluronic acid (Wong and coworkers, 1981; Higson and coworkers, 1988). The use of vitamin B $ as a primary agent in combination with co- agents such as vitamins C, E, A, B,, B 5 , as well as dimethyl sulfoxide, PABA, inositol , selenium, butylatcd hydroxytolucnc , thiodipropionatos , choline, cysteine, zinc and D-ponicillαmino has been described for clinical treatment of arthritis, together with use of a water bod (Pearson and Shaw, 1982, pp. 298-300) . Numerous other variations on this list of co-agents have been described publicly (see Passwator, 1985) . The disclosure of Pearson and Shaw contains several deficiencies which are resolved by the present invention. They did not recognize the pro-oxidant, the lipid peroxidation stimulating or the protein glycosylating properties of vitamin C. Noting these deleterious properties of vitamin C, this inventor regards ex¬ cess vitamin C consumption (beyond the RD , 60 mg/dαy) to bo α risk factor for exasperating the physiological and clinical effects of arthritis and other chronic inflammatory diseases. In contrast, Pearson and Shaw (1982) refer repeatedly to vitamin 0 as the primary agent of their many compositions (for example, pgs. 468-469 and 611-613) . Nor did Pearson and Shaw recognize the ability of aldehyde trap¬ ping agents such as PABA to chemically react with and sequester aldehydes which may result from and contribute to the inflamma¬ tory cascade process. This inventive oversight on their part is of fundamental importance. This explains why Pearson and Shaw listed PABA only as one of many "αnti-oxidant" and "membrane stabilizer" co-agents. In contrast, PABA and derivatives there¬ of are identified as the class of primary agents in the present invention. At least two other deficiencies of the Pearson and Shaw prior art disclosure are addressed by the present invention. D- Pcnicillaminc has been recognized as an anti-arthritic drug based on its abilities to inhibit lipid peroxidation by neutralization of free radicals and to bind iron or copper ions (Kostyuk and coworkers, 1990, pg. 39; Domopoulos, 1973, pgs. 1904 and 1906) . D-Penicillaminc has known predictable long term toxic properties which severely limit its practical use on humans (Dcmopoulos, 1973, pg. 1906; Zuckcrman and coworkers, 1980, pg. 430) . Its toxic properties prevent its use on α long term, on-going basis, as required for the clinical treatment of the disorders addressed heroin. In addition, L-cystoino has been recognized as a neurotoxic agent when used under certain laboratory circumstances (Olnoy and coworkers, 1990) . As Olnoy and coworkers stated, "after systemic administration to immature rodents, L-cysteino destroys neurons in the cerebral cortex, hippocampus, thalamus , and straitum..." (pg. 596) . Hence use of cysteine is also deleted from the present invention. Zarafonctis (1953) has reported some success in treatment of rheumatoid arthritis by use of potassium p-aminobonzoatc in com¬ bination with acctylsalicvlic acid and cortisone. In this report Zarafonctis also described some success in clinical treatment of dcrmαtomyositis and scleroderma by use of potassium p-αminobonzoαte alone, and referred to earlier work on these disorders and other clinically related syndromes, including forms of lupus erythematosus. Yet Zarafonctis based his logic for diversifying clinical stud¬ ies on PABA or its potassium salt solely on similarities of clinical symptoms, comparisons among clinical syndromes which feature some common symptomology (Zαrαfonoti , 1953, pp 667-668; Zarafonctis, 1964, pgs. 550 and 560; Priestley and Brown, 1979, pg. 161; Zarafonetis and coworkers, 1988, pg. 194) . Zarafonotis never stated an understanding or recognized that PABA has the physiological potential of serving as an aldehyde chemical trapping agent (Zarafonetis, 1953, pg. 671) . Hence, he never recognized its potential to sequester aldehyde products result¬ ing from increased lipid peroxidation secondary to site-specific inflammation. In failing to recognize this principle, Zarafone¬ tis failed to recognize the potential full scope of clinical applications of PABA. Failing to recognize the potential of syncrgistic antioxidant co-agents, the procedures of Zarafonctis for treatment of scleroderma, rheumatoid arthritis and dermato- myositis relied on use of high PABA dosages (12-18 gm/day; sec Zarafonetis, 1953, pg. 666) . In principle, it is the under¬ standing of this inventor that the clinical prognosis of any disease which features increased lipid peroxidation as part of its etiology may be improved by clinical application of the present inventive concept. Zarafonctis (1953) also referred to an earlier study which used α combination of p-aminobonzoic acid and alpha- ocopherol to treat scleroderma. Gougcrot and Hewitt (1951) described the logic of their scleroderma treatment protocol as fol.-. ws: This observation is to be added to the file of the treatment of sclorodormas . Zarafonotis and his collaborators have already published 5 cases of sclorodormas improved by para-amino- benzoic acid, and in the same therapeutic scries Chaffer and his collaborators treated a gener¬ alized scleroderma with para-aminobonzoic acid with improvement . In a study of a completely different nature, vitamin E ( -tocopherol ) was used by Klcmpcrcr, etc. and in France by Bαzcx (Lyon, July 1949) . This is why wo have associ¬ ated the two therapies because of their effect on diseases of collagen. As such, they perceived their clinical treatment strategy to ad¬ dress the status of collagen, with no discussion of possible physiological mechanisms. Compared to the present invention, Gougerot and Hewitt: (1) failed to recognize that cither of their therapeutic agents may interfere with the inflammatory cascade, (2) failed to recognize that primary amino and amine-related derivatives of benzoic acid, as a class, may bind to and sequester aldehydes which result from the inflammatory process, and (3) failed to understand that the combination of a water soluble aldehyde-trapping primary ammo agent and a lipophilic antioxidant agent may have clinical application to the treatment of a broad spectrum of chronic inflammatory diseases . One additional clinical study based on use of PABA falls within the scope of prior art regarding the present invention. In 1967 Mcl'nikova and Ryzhova presented the results of a clinical trial wherein PABA was used to treat post-event trauma in experimental myocardiual infarction, as studied in rabbits and dogs. Myocar¬ dial infarction was induced by silk ligature of the left coro¬ nary artery and vein. Mcl'nikova and Ryzhova reported, in part: One of the more important problems facing modern pharmacology is the search for substances capable of restoring the circulation of the heart in myo¬ cardial infarction. Improvement in the coronary circulation may be obtained both by a direct cor¬ onary-dilator effect on the vessels of the heart and by influences acting on metabolic processes and the hemodynαmics in the heart muscle. From this point of view there is considerable interest- in procαino and the product of its hydrolysis - p-aminobenzoic acid (PABA) , an active component of procaine, taking part in intimate biochemical pro¬ cesses and possessing a well-defined antihistaminc action... (pg . 389) The animals of scries II (25 rabbits and 5 dogs) with an acute myocardial infarct received subcu¬ taneous injections of PABA in doses of 12-15 mg/kg daily, twice a day throughout the period of obser¬ vation. Examination of the clcctrocardiographic, clinical, and laboratory findings for the rabbits and dogs treated with PABA (12 mg/kg) on the second day showed restoration of the normal rhythm with disappearance of the cxtrasystolc , an increase in the voltage of the waves, and some reduction in the depth of the QS waves, evidently as a result of im¬ provement of the coronary circulation...On the 9th- 14th day, in 85* of the animals (receiving 12 mg/kg PABA) the ECG and results of the clinical and labor¬ atory investigations were normal, while in the re¬ maining 15* of animals, organization of the myocardial infarct took place on the 16th-18th day...(pg. 390) Special attention was drawn to the well marked vas- cularization both in the areas of connective scar tissue and throughout the myocardium, mainly as a result of dilatation of the capillaries and an increase in the number of arteries, and also to the absence of necrosis in the perifocal zone. In acute experiments on cats (by N. V. Kaverina's method) a constant and well marked coronary-dilator effect was observed in response to injection of PABA (15-20 mg/kg), as shown by a considerable increase in the volume velocity of the coronary blood flow (by 80- 108*) and also by a distinct reduction in the oxygen consumption of the heart... (pg. 391) As such, Mcl'nikova and Ryzhova have reported a coronary vaso¬ dilator effect of PABA based on their understanding of the drug's antihistαmino property. They recognized no αnti-inflαm- atory property of PABA and did not understand their findings within such α context. Subsequent work by Kurdin (1973) has presented evidence of increased lipid peroxidation in the pro¬ cess of myocardial infarction. Viewing both of these studies within the context υf the present invention, the inventor proposes that, to some degree, the beneficial effects of PABA in the Mcl'nikova and Ryzhova study reflected an anti-inflammatory property of PABA unrecognized by the investigators, and that such a beneficial effect may be optimized by use of the multi- component compositions of tho present invention. As defined below, the present invention is believed to have significant clinical value in tho post-event treatment of myocardial infarction, acute central nervous system trauma and stroke. United States Patent No. 5,002,703 (Warner-Lambert Co.) is entitled "Benzoic acid and benzoic acid ester derivatives having αntiinflammatory and analgesic activity." It's utility is des¬ cribed as applying to "...treatment of arthritis, asthma, Ray- naud' s disease, inflammatory bowel disorders, trigeminαl or herpctic neuralgia, inflammatory eye disorders, psoriasis, den¬ tal pain, and headaches, particularly vascular headache, such as migraine, cluster, mixed vascular syndromes, as well as nonvas- culαr , tension headaches." Tho mechanism of action as defined in this patent is different from the inventive concept of the present invention, the primary agents of tho Warner-Lambert procedures arc substantially different from those of the present invention, and tho Warner-Lambert procedures do not involve multiple-ingredient compositions analogous to those of the prosent invention. All Warner-Lambert US patents of the series represented by US Patent 5,002,703 arc based on claims regarding compounds which arc, by comparison ro the present invention, relatively largo, complex chemical derivatives of benzoic acid. For example, the primary -.gents of US Patent 5,002,703 arc described as: A compound or the formula R 1( (Q-Rτ-B-N(-Y)-CII(-X) -)bcnzcnc wherein: (a) R, is COOR 1 wherein R 1 is H or lower alkyl of one to four carbons, inclusive; (b) B is -SO,-; (c) X and Y arc independently H or lower alkyl of one to four carbons, inclusive; (d) R, is alkylene, alkcnyleno, alkynylone branched or linear chains of 1 to 11 carbons, inclusive; (c) Q is C00H, Br, NH,, cyclohexyl, or 2-naphthyl-0-; or nontoxic, pharmaceutically acceptable acid addition or base salt thereof. Chemical structures of this kind clearly lie beyond the claims of tho present invention. Broad spectrum clinical use of anti-inflammatory vitamin com¬ positions which feature PABA as a primary agent, and the methodological reasoning ror doing so, has not been previously recognized or described. p-Aminobonzoic acid is not presently recognized as a non-stcroidal anti-inflammatory drug (NSAID). Hence, for example, it is not included in the lists of such drugs published in (a) the Merck Index, (Budavari, 1989, pages THER-15 to THER-16) , (b) Scientific American (Weissmann, 1991, page 86), and (c) Understanding Arthritis (Kushncr, 1984, pages 52-53) . Likewise, p-aminαbcnzoic acid is not recognized as being α "slow acting" anti-inflammatory agent (Understanding Arthritis , Kushncr, 1984, pages 55-57) . Indeed, in a feature article entitled "The new scoop on vitamins," Time magazine (Toufoxis, 1992) failed to mako any reference whatsoever to PABA. SUMMARY OF THE INVENTION These and other objects of this invention are achieved by pro¬ viding a novel method for clinical treatment of chronic inflam¬ matory diseases. This invention involves use of orally admin¬ istered amine and amine-related derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering tho aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have boon repeatedly demonstrated as a part of the "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid is an example of the primary absorbablc pharmacological agent of the present invention. PABA has α small molecular weight, is water soluble, has a primary amine group which should react with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The present invention sets forth the belief that carbonyl sequestering agents administered in oral dosages may bo used in combination with co-agents consisting of proven antioxidant free radical trapping agents, and agents related thereto, so as to produce α syncrgistic physiological effect of an anti-inflammatory and analgesic nature. Co-agents of the present invention include antioxidants (such as alpha-tocophcrol ) , suspending reagents (such as carboxymethyl cellulose) , other vitamins, vitamin- related agents (such as carnitinc) , chemical conjugating agents which may facilitate kidney drug elimination (such as glycine) , and orally administered non-absorbable polyamine or polyamine- related agents (such as chitosan) . 1. Aims of the Invention Accordingly, it is a general object of this invention to treat the symptomology of chronic inflammatory diseases and otio- logically related symptomology by use of carbonyl trapping agents in combination with known antioxidant free radical trapping co-αgcnts and factors related thereto, so as to create compositions with additive, complimentary physiological Thera¬ peutic characteristics. It is a further object of this inven¬ tion to facilitate the effectiveness of this anti-inflammatory and analgesic procedure by use of orally consumed carbonyl trapping agents which are of a non-absorbable nature, so as to bind and sequester carbonyl chemical agents which arc present in food, thus preventing such toxic agents from being absorbed into the body. In particular, it is an object of the present invention to use αbsorbablo amino and amine-related primary agents, non-absorb¬ able amine and aminc-rclatcd polymeric co-agents, co-agents which inhibit lipid peroxidation, vitamin co-agents which may bo inadvertently depleted, vitamin-related co-agents, co-agent metabolites which may be depleted within tho body, sulfhydryl co-agents, co-agents which may facilitate glutathionc activity, so as to improve upon tho prior art. It is an object of the present invention that the drug composi¬ tions described heroin may provide clinical value in tho treat¬ ment of disease symptomology for disorders featuring lipid peroxidation and resultant formation of toxic carbonyl com¬ pounds, including: chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstruc¬ tive pulmonary disease, chronic obstructive pulmonary disease, Lymc disease, inflammatory myopathics , status epilepticus, inflammatory neuropathies, myasthenia gravis, multiple sclero¬ sis, as well as lessening of inflammatory site edema, and post- event ischemia and repcrfusion injury resulting from acute central nervous system trauma, stroke, kidney ischemia or myocardial infarction. It is another object of the present invention that in so far as tho cherαpeutic procedures described heroin may serve to delay the necessity of initiating the use of known medicaments or to decrease the dosages of known medicaments reguirod to achieve beneficial effects, the period of prior art drug therapeutic value may be extended and detrimental clinical side effects resulting from use of known medicaments may be decreased, so that overall patient treatment may bo improved. It is a further object of this invention that the absorbablc αmino and amine-related substances and derivatives thereof described herein when used in combination with specified co- αgonts may bo clinically applied to treat veterinary disorders comparable to at least some of those human disorders described above . 2. Statement of Invention It is known that aldehyde chemical metabolites, which contain carbonyl functional groups, arc generated during the process of chronic inflammation. Those aldehyde products result from pathologically increased lipid peroxidation, which may be initi¬ ated by a variety of activated oxygen chemical species such as the hydroxyl radical, HO- (Halliwell and Gutteridge, 1985, pp. 119-120) . The reactive cascade of free radical propagation -→ lipid peroxidation — aldehyde formation and other subsequent effects of inflammation is well documented in the prior art (Halliwell and Gutteridge, 1985, pp. 102-103) . The concept of using carbonyl-trapping agents such as primary amine or amine-related derivatives of benzoic acid to treat chronic inflammatory diseases has not been recognized or dis¬ closed. Thus, the application of this principle in conjunction with use of known antioxidant free radical trapping agents to produce new and novel compositions which have improved, syner- gistic therapeutic properties also has not been recognized. When compared to previously disclosed understanding of the actions of recognized non-steroidal anti-inflammatory drugs (Weissmann, 1991) , it is evident that the inventive concept described herein represents c. new approach to the treatment of chronic inflammatory disorders. Previously, attempts at pharmaceutical intervention in this cascade of inflammatory reactions has focused primarily on use of both water-soluble and lipid-soluble antioxidant free radical trapping agents or use of metal chelαting agents (Halliwell and Gutteridge, 1985, pp. 125 and 116-117) . As iron and copper ions have been shown to induce hydroxyl radical formation (Halliwell and Gutteridge, 1985, pg. 123) and induce lipid peroxidation (Halliwell and Gutteridge, 1985, pg. 124) , the use of metal chclating agents such as desfcroxaminc to ameliorate the inflam¬ matory cascade has received some attention (Halliwell and Gut¬ teridge, 1985, pp. 116-117) . However, desfcroxaminc has pre¬ dictable ocular and auditory side effects (Halliwell and Gut¬ teridge, 1985, pgs. 117 and 140) , and present examples of anti¬ oxidant free radical trapping agents and combinations thereof have proven to be of limited clinical value. Both PABA and penicillamine are primary amine agents which also function as antioxidant free radical trapping agents. Yet as antioxidant agents PABA and penicillamine are presently regarded as being of secondary, nominal value, due cither to weak anti¬ oxidant properties or toxic side effects, respectively. Thus their use as anti-inflammatory agents has been guitc limited. Their potential value for trapping the aldehyde products of inflammation-related• lipid peroxidation has never been recog¬ nized. τ-?.-»nco i" ' ^ formul. ' . ion of α now composition, such as one having PABA as its primary agent, known antioxidant free radical scavenging chemicals as co-agents and lacking vitamin C, has never been previously described, and the potential for clinical use of such α novel composition in treatment of chronic inflam¬ matory diseases never recognized. Further distinctions should be made between the present inven¬ tion and previously recognized use of penicillamine, one of the "slow-acting" anti-inflammatory drugs mentioned in Under tanding Arthritis (Kushncr, 1984) , a publication of the Arthritis Foundation. The primary amine and αmine-rclatcd rrinciplc agents described in the present invention are all derivatives of aminobcnzoic acid, which should facilitate their safe elimina¬ tion from tho body by normal kidnov filtration . Penicillamine is not a derivative of aminobcnzoic acid. In addition, penicil¬ lamine has a reduced sulfhydryl group, unlike any of tho primary agents claimed herein. However, penicillamine docs have a primary amino functional group as well as a carboxylic acid functional group, like aminobcnzoic acid. In Understanding Arthritis Kushner noted that: Many doctors believe that the slow-acting drugs may slow the underlying disease, though how they do this is not clear. This group of drugs includes gold, penicillamine, cytotoxic, and antimalarial drugs. All of the drugs in this group have to be taken for many weeks, and often for several months, before their full effects become noticablc. The relief they provide may last for some time after they are no longer being taken. But with these benefits of long-lasting relief and a possible slowing of tho disease also comes a higher risk of serious side offects ... (pages 55-56) ...Again, tho sido effects [of penicillamine] often require some people to stop taking this drug. Like gold, penicillamine may damage the kidneys and bone marrow, and may also cause fever, chills, rashes, sores in the mouth, α soro throat, stomach upset, muscle weakness, loss of taste, and easy bruising or bleeding. Because of these possible side effects, the drug is taken only with close supervision by a doctor ... (page 57) The present invention constitutes an alternative slow-acting anti-inflammatory composition which is believed to be inherently safer for tho patient and act via a mechanism not previously recognized or described. A review of the article by Wcissmann (Scientific American, 1991, pages 84-90) will serve to illustrate the distinction between the πresent invention and prior art development of non-stcroidal αnti-inflammatory drugs. Tn discussing presently recognized understanding of the actions of NSAIDs, Wcissmann stated, in part : NSAIDs act by blocking the production of both PGGi and PGH,. Platelets transform the latter into a most potent vasoconstricting and platclct-αggrcgating sub¬ stance, thromboxαne B,... (page 07) ...Aspirin irreversibly inactivates PGH synthasc [i.e. , prostaglandin H synthaso] . Platelets cannot mako more synthasc and so make no more thromboxanc ... less than one tablet a day can irreversibly block the PGH synthaso activity of platelets ... (page 88) Vane's theory that the local production of prosta- glandins leads to inflammation has only partly been sub¬ stantiated, however ...aspirinlike drugs exert clinical effects that do not depend on inhibiting prostaglandin synthesis ... (page 88) The broad spectrum of NSAID effects most likely re¬ sults from their physical properties, which permit them to disrupt interactions within biological membranes... For example, aspirin alters the uptake of fatty acids and their insertion into the membranes of cultured human monocytes and macrophagos . Salicylαtos also inhibit anion transport across a variety of cell membranes. Fi¬ nally, NSAIDs inhibit bone metabolism and tho synthesis of protcoglycan, a substance that forms the matrix of cartilage... (page 38) Recent work in my laboratory has uncovered an alter¬ native mechanism for tho effects of αspirinlike drugs: interference with stimulus-response coupling in neutro¬ phils, the most abundant cells of acute inflammation. These cells are the first line of defense against for¬ eign intruders and among the first to cause injury in autoimmune diseases like rheumatoid arthritis. They ' damage tissues by releasing enzymes that break down proteins (proteases) , as well as inflammatory peptides, reactive oxygen species such as 0, " and H^O, (peroxide) , and lipid irritants such as platelet-activating factor and leukotriono B,. (pages 88-89) ...Both 'homotypie' adhesion between neutrophils and ' hetorotypic ' adhesion of neutrophils to the walls of blood vessels arc rcguired for cells to make their way out of tho circulatory system and to cause inflammation... It is therefore likely that the anti-inflammatory effect is related to tho ability of both [sodium salicylato and aspirin] compounds to inhibit homotypie and heterotypic dhesion in neutrophils rather than to thoir unequal effect on prostaglandin synthesis... All NSAIDs inhibit the homotypie adhesion of neutro¬ phils, but they differ in their effects on other functions of the noutrophil ... (page 89) Some of the effect of NSAIDs on cells arises from inter¬ ference with tho binding of chemoattractants and other stimuli. These drugs inhibit the binding of at least some of these ligands with their receptors in the coll mem¬ brane ...NSAIDs interfere in particular with signals that depend on so-called G proteins for trαnsduction through cell membranes, (page 90) The present invention, by contrast, depends on α fundamentally different mechanism of action. The present invention is based on use of primary amino or amine-related derivatives of benzoic acid as principle agents for chemically binding to and seques¬ tering aldehyde products of inflammation site lipid peroxidation in combination with previously recognized antioxidant free radi¬ cal trapping co-agents. This unique, multiple-level approach to interference with certain steps in the inflammatory cascade has not boon previously recognized by other research investigators. This is, in fact, the first anti-inflammatory agent invention which addresses the issue of aldohydo formation at inflammation sites. As aldehydes arc highly reactive molecules capable of reacting with oroteins, lipids and nucleic acids (Jolluin and coworkers, 3973, pg. 200; Harden and coworkers, 1986) , their increased formation at inflammation sites may be a significant contributing factor in the evolution of the clinical pathology of inflammatory disorders. Halliwell ana Gutteridge (1985. pg. 123) noted that maionaldchydc ...is only ono of a groαt number of carbonyl compounds formed in pcroxidising systems and often is only a tiny percentage of the total products forme ...Other toxic aldehydes include 4 , 5-dihydroxydcccnal and 4- hydroxynononal . Lipid peroxides αnd/or cytotoxic aldehydes derived from them can block macrophagc action, inhibit protein synthesis, kill bacteria, inactivate enzymes, crosslink proteins and generate thrombin... The results of several published research studios suggest that dysfunctional lipid peroxidation may be a contributing factor in the etiology of a variety of chronic inflammatory diseases, such as rheumatoid arthritis (Rowley and coworkers, 1984) , multiple sclerosis (Huntor and coworkers, 1985), silicosis (Katsnelson and co-workers, 1989, pg. 318), Duchcnnc muscular dystrophy (Kar and Pearson, 1979; Jackson and coworkers, 1984) , and chronic inflammatory bowel disease (Ahnfclt-Ronnc and coworkers, 1990) . As exposure to asbestos fibers can stimulate lipid peroxidation (Halliwell and Gutteridge, 1985, pg. 152), asbestosis should also be included in this category. Increased lipid peroxidation has also been demonstrated in acute central nervous system trauma (Hall, 1987, pgs. 421 and 424; Domopoulos and coworkers, 1980, pg. 97; Kontos and coworkers, 1981, pg. 2329) , as a result of stroke (Zivin and Choi, 1991, pg. 61) and subsequent to myo¬ cardial infarction (Kurdin, 1978) . Status epilepticus is one of several clinical disorders which have been linked to increased intracellular concentrations of free radicals, with subsequent lipid peroxidation (Del Maestro, 1980, pg . 163) . Likewise, published evidence has documented the ability of carbonyl com¬ pounds resulting from lipid peroxidation to induce foot edema in the rat (Benedetti and coworkers, 1980) . i 3) Detailed Description of the Prcrcrred Embodiment Tho inventive feature disclosed in this text i . that composi¬ tions consisting of absorbablc carbonyl trappmq drugs in :ombination with known antioxidant free radical trappinσ <- ~ ασcnts may be of particular syncrgistic benefit in preventing or ameliorating forms ot chronic inflammation by incorporating two pharmacological strategies, the sequestering of cytotoxic alde¬ hydes and ketones generated at sites of chronic inflammation and the seguestering of activated oxygen chemical species generated earlier in the inflammatory cascade. It is further understood that oral use of non-absorbable carbonyl trapping agents may serve to prevent absorption of dietary aldehydes and ketones rrom the alimentary tract into the body, thus complementing the intended therapeutic results. (i) Mechanism of Action of Primary Agents For the most part, these pharmacological reactions are based on the ability of primary amine compounds to react with aldehyde functional groups of potentially toxic agents, yielding co¬ valently bound Schiff base products. Several examples of chem¬ ically analogous reactions, presented within othor contexts, have been publicly presented. Representative examples are discussed below. These model chemical systems are directly analogous to the proposed mechanism of drug action which is the basis of the present invention. Comments by Feeney and coworkers (1975, pg. 141) provide an appropriate introduction to this subject: A wide variety of substances with -NH, groups con¬ dense with carbonyl compounds ...This condensation of primary amines with aldehydes and ketones to give iminos was first discovered by Schiff (1900) . Tho overall equilibrium greatly favors hydrolysis in iqueous solution ror aliphatic aldehydes. With aromatic aldehydes, the equilibrium is shifted in favor of Schiff base formation. It is important to note that increasing the nuclcophi _1 i c strength of tho αmine will increase the rate of the carbonyl- aminr reaction but will have almost no effect on the position of the equilibrium. These comments suggest that the: aminc-containing carbonyl- trapping drugs described heroin should have particular promise for binding furanal chydes , which arc aromatic. Those comments also suggest that doses of αbsorbablc amine drugs may require in vivo concentrations in the range of 1:100 to 1:1,000 (carbonyl: amine) in order to achieve clinical effectiveness. This, in turn, suggests that therapeutic dosages may lie in the range of grams per day and that only drugs of particularly low toxicity will have human applications. Fecney and coworkers (1975, pg. 144) also noted the phenomenon of Schiff base transimination, which occurs to a significant extent at neutral pH: The existence of such non- cnzymatic reversible transimination reactions is important within the context of this invention, as it suggests that in vivo both bound carbonyl agents, in addition to free carbonyl agents, may be sequestered by aminc-containing drugs . (a) The direct in vitro addition of p-aminobenzoic acid or ethyl p- aminobenzoate to malondialdchydc or its tautomcr, bcta- hydroxyαcrolein, has boon described (Sawicki and coworkers. 3963) . H This report also described the reaction of aminobenzene (that is, aniline) with maionaldohyde. Tho metabolic fate of PABA in humans has been actively investigated and well reported in the biomedical literature (Young and coworkers, 1971; Howie and Bourkc , 1979). It is so actively metabolized via several mech¬ anisms and guantitativoly removed in urine (Weizman and cowork¬ ers, 3985; Bingham and Cummings, 1983) that PABA excretion has become a widely recognized standard for measuring urinary clearance. Small amounts of PABA arc normally present in the human diet. It is recognized as being a vitamin for many organisms and is classified as a member of the vitamin B complex (Smith, 1976, pg. 194; Winitz and coworkors, 1970, pgs. 527-528; Scott and Robbins, 1942) . As a vitamin for human use PABA is commercially marketed in the United States in the dosage range of 5 to 550 mg/day. (b) Self-polymerization of o-aminobcnzaldchydc has been des¬ cribed. In the 1993 edition of tho Sigma Chemical Company catalog of biochemical reagents the following statement appears on page 87 of its listing: "o-AMINOBENZALDEHYDE Unstable! [store at] -20^ Polymerizes rapidly when exposed to room temperature. May yield slightly hazy solution in ethanol due to presence of a small amount of polymer. Shipped in dry ice." This informa¬ tion directly indicates that α primary amino group covalently linked to a benzene ring possesses sufficient reactivity for significant reaction with aldehyde functional groups at room temperature. It is apparent that no form of activation of the αmino group is required and that a Schiff base product forms readily. (c) The direct i_n_ vitro addition of n-hcxylamine to bcta- hydroxyacrolein to produce an N,N' -disubstituted l-amino-3- iminopropene derivative has boon reported (Ohio and Tappol, 1969) . The reaction may ' be represented as follows: -Hp -t-H^-R 0=CHCH=CHOH + HJ*-R ,»-0=CHCH=CH-NH-R >-R-N=CHCH=CH-NH-R -H 2 0 I enamine N,N'-disubstituted l-amino-3-iminopropene where I = beta-hydroxyacrolein (d) Tho direct chemical addition of amines to 5- methyl- 2- furfurαl has been described (Holdren and Hixon, 1946) . A wide variety of aliphatic and aromatic primary amines can add to furfural in this manner,, yielding Shiff base products (Dunlop and Peters, 3953, pq . 353) . (e) As described by Dunlop and Peters (1953, pg. 373) earlier work demonstrated the ability of to react with amino- sulfonic salts to produce furfurylideneαminosulfonαto . (f ) The reaction of phenylaminoguanidine with furfural (Dunlop and Peters, 1953, pg . 371) may serve as an example of covalent furanaldchydc trapping with a hydrazine. It is proposed that the small molecular weight, αbsorbαble , primary amine drugs and aminc-rclatcd drugs described herein will have analogous behavior in vivo, as well as an additional characteristic which will facilitate disposal as urine metabo¬ lites. All of these drugs contain a carboxylic acid group to facilitate uptake and processing by the kidneys. (ii) Examples of Absorbαble Drug Primary Agents For any carboxylic acid primary agent listed herein as useful in the present invention, it is believed that the salt forms, free acid form, ester derivatives, amide derivatives and analogous non-aromatic benzene ring derivative (that is, cyclohexane car¬ boxylic acid derivative) thereof will also be useful. The class of primary agents (molecular weight range 100 to 1,400) of the present invention may be summarized as noted below in chemical structures I, II and III. R = -NH ? -aminoalkyl group having 1-10 carbons including hydrocarbon isomers and/or hydroxylated derivatives thereof -NHC(^NH)NH 2 -(CH ? ) n NHC(=NH)NH 2 whore n = 1-10 -C(=NH)-NH 2 -( CH 2 ) n -CH=NC( =NH)NH 2 whore n = 1-10 -NHC(=NH)NHNH. -( CH 2 ) n NHC( =NH)NHNH ? where n = 1-10 - (CH 2 ) n -CH=NC(=NH)NHNH - where n = 1-10 -NHNHC(=NH)NH -(CH 2 ) n -NHNHC(=NH)NH 2 where n = 1-10 - ( CH ,) n - CH=N-NHC( =NH)NH , where n = 1-10 R, = -NH-, -aminoalkyl group (1-10 carbons ) including hydrocarbon isomers and/or -NHC(=NH)NHNH- ( continued) (CH -,) $mci =NH)NHNH whore n = .1 10 ( CH. CH=NO ( -NH)NHNH where n - 1-.10 ■■ NHNHC(=NH)NH., ■ ( CH,) π -NHNHC ( =NH)NH, where n = 1-10 CH. ■ CH=N-NHC(=NH)NH where n = .1- R. -NH ? -OH ' with lkyloxy group R' having 2- 10 carbons including hydrocarbon isomers and/or hydroxylated derivatives thereof ■ aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof including hydrocarbon isomors and/or hydroxylated derivatives thereof = 0-10 s of roup eof -(CH ? ) n -CH=NC(=NH)NH, where n = 1-10 - ( CH 2 ) n - ■ CH=NC(=NH)NHNH- where n = 1-10 -NHNHCi =NH)NH, -(CH ? ) η -NHNHCI =NH)NH, where n = 1-10 - ( H ?) r| CH=N- NHC(=NH)NH where n = 1-10 continued -H -OH y rocar on somers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof including hydrocarbon isomers and/or hydroxylated derivatives thereof R 1 = -H -CH 3 -OH R" = -H - -CCH 3 -OH (iii) Mechanism of Action of Non-Absorbable Primary Amino and Amine-Rclatcd Agents Tho presence of aldehydes and ketones in tho human diet may be a factor which may put the patient suffering from a chronic in¬ flammatory disease further at risk. This might bo especially important for victims of ileitis and colitis, as the damaging effects of inflammation site carbonyl compounds may be accentu¬ ated by direct exposure to dietary carbonyl agents. 5-Mcthyl furfural has been identified in the oil of roasted coffee and in oil of cloves (Dunlop and Peters, 1953, pg. 403) . 5-Hydroxy- methyl furfural has been found in sherry, port and brandy alco¬ holic beverages: honey and other sugar syrup products (Lever and coworkers, 1985) . Levels of furfural (that is, 2-furanaldehyde or ?-furancarboxaldohydc) and 5-hydroxymcthyl-2-furanaldehydc (that is, 5-hydroxymethvl furfural) as high as 4.5 mg/L and 93.2 mg/L, respectively, have been found in wine products (Shimizu and Watanabα, 1979) . Furfural has also been detected in boor and distilled liguors (Dunlop and Peters, 1953, pg. 308) , as well as in natural oil products such as oil of lime (Dunlop and Peters, 1953, pg. :._80) . Summarizing earlier work, Rice (1972) noted: Small quantities of furfural occur in many foodstuffs, including - among many others - bread, coffee, pro¬ cessed fruits and fruit juices, and alcoholic bever¬ ages. In fact, whenever plant or animal tissue con¬ taining pentoscs or hexoscs is subjected to heat, the possibility arises that furfural, 5-hydroxymothyl furfural, and probably other furans as well will be produced. Pettersen and Jcllum (1972) referred to earlier work which de¬ monstrated the generation of 2-furanaldehydε, 5-hydroxymethyl-2- furanaldehydc and 2 ,5-furandicarboxaldchydc during bread baking. In his food chemistry study, Baltes (1985) noted the presence of furfural in curing smoke tar; and the presence of furfural, 5- methyl-2-furfural , dihydrofuranone, 5-hydroxymethγl-2-furfural and ,5-furandialdchyde in caramels. Baltes also examined the products obtained by Maillard reaction of glucose and phcnyl- alanine and identified furfural and 2 , 5-di-(hydroxymethyl ) -furan among the main components. Thus various furan aldehyde com¬ pounds have been identified in the human diet. In addition, α wide variety of naturally occurring non-αromatic and aromatic aldehydes and ketones have been found in fruits and vegatablos (Schauonstein and Esterbauor, 1977, pgs. 181-194) . These include alkanals, alk-2 , 4-dicnals, alk-2-cnals, alk-l-en- 3-onos, alpha-dicarbonyl compounds, beta-dicarbσnyl compounds alkan-2-ones . Schaucnstein and Estabaucr have noted, in part, that: Aliphatic carbonyl compounds represent the most important group of flavouring compounds in our foodstuffs. One finds them in all flavour extracts. They are cither entirely, or in large measure, responsible for nearly all known flavours and determine, even when present in small amounts, the taste and odour of our foodstuffs, and beverages such as tea and coffcc... (pg. 189) As the presence of carbonyl agents in the diet is not restricted to fruits and vcgatablcs , Schaucnstcin and Estabaucr have fur¬ ther noted that: Unsaturated aldehydes also arise through thermal degradation of carbohydrates, amino acids, and f ts. Such thermal degradative processes arc probably responsible for tho presence of these aldehydes in boiled, fried, and baked foods. Unsaturated alde¬ hydes have been detected in a large number of food¬ stuffs, such as potatoes, potato chips, poultry, meat, fish, salad oils, bread, and bakery products ... (pgs. 193-194) As such, it is apparent that the diet is a significant source of carbonyl agents, and their presence may be a contributing factor in the etiology of chronic inflammatory diseases. Toxic proper¬ ties of aliphatic aldehydes are well known, and toxic properties of furanaldehyde derivatives have been demonstrated in both in vivo and in vitro studies (Konecki and coworkers, 1974; Ulbricht and coworkers, 1984) . It is proposed that non-absorbable dietary supplements such as those defined below can bo of health benefit by virtue of their ability to covalently trap dietary aldehydes and ketones. The agents described in this section can accomplish this function because they bear primary amine groups or derivatives thereof. As largo molecular weight molecules which are non-digcstiblc they have the capacity to pass through the digestive tract, acting in effect as another form of dietary fiber. These non- absorbable substances may be divided into three classes: (1) naturally occurring polyamine polysaccharides, (2) chemical derivatives of naturally occurring polysaccharides, and (3) synthetic polyamine polymers. Tho fate of malondialdohyde given orally to rats may servo as an example of the metabolism of dietary aldehydes, and how an understanding of this process can be used to define non-αbsorb¬ able carbonyl-trapping drugs. Studies by Draper and coworkers (1986) demonstrated that the primary form of "bound" MDA in rat or human urine is N-alpha-acetyl-epsilon-( 2-propcnal) lysinc . This is the biologically alpha-N acotylated derivative of the MDA-lysinc adduct N-cpsilon-( 2-propcnal ) lysinc , as shown below. Draper and coworkers (1986) wore able to generate N-epsilon-( 2- propcnal )lysinc in vitro by exposing beef muscle protein to MDA, followed by treatment with pepsin and hog intestinal juice. This indicates that the opsilon-amino groups of dietary protein H 3 C-C=0 \ COOH N-alpha-acetyl-epsilon-(2-propenal)lysine NH, O / II CH-CH 2 -CH 2 -CH 2 -CH 2 -NH-CH=CH-CH COOH N-epsilon-(2-propenal)lysine lysine residues can covalently bind dietary aldehyde under conditions found in the intestinal tract. As such, chemically analogous primary amino groups on non- bsσrbablo drugs should also be capable of covalently binding dietary aldehydes under conditions to be found in the intestinal tract. In this case, however, the bound carbonyl species would be excreted in the feces , thus preventing subsequent in vivo exposure to dietary carbonyl agents. In their study Draper and coworkers noted that N-alpha-acctyl- epsilon-( 2-propenαl ) lysine was found in urine of fasted rats or animals fed on MDA-frec diets, indicating that the MDA-lysinc αdduct also forms in vivo. Those investigators referred to earlier work which demonstrated that the MDA concentration nor¬ mally found in food is in the range of <0.1 to 10 ppm (0.1 to 10 uM) , which gives some idea of dietary aldehyde concentrations. (iv) Examples of Non-Absorbable Drug Products Useful in the Present Invention (a) . Naturally Occurring Amine-Containing Polysaccharides Any naturally occurring polysaccharide featuring beta-1,2, bota- 1,3, bcta-1,4 and/or bcta-1,6 linkages which contains amino- sugars may be regarded as a non-digestible, potentially active carbonyl trapping agent. The chitin class of biopolymcrs may be cited as an example of such an agent, having tho general structure of poly-beta-(1— 4)-N-acetyl-D-glucosamine. A form of microcrystalline chitin has been described in which some of tho acetyl groups have been removed, revealing free amine groups (Austin and coworkers, 1981, pg. 750) . Chitins obtained from different sources feature different degrees of amine deacctyl- αtion (Austin and coworkers, 1981, pg. 752) . (b) . Chemical Derivatives of Naturally Occurring Polysaccharides Various pretrcatment procedures may be applied to naturally oc¬ curring polysaccharides prior to generation of chemical deriv¬ atives. Generation of microcrystalline polysaccharides is one example of such a protroatment procedure. As applied to cellu¬ lose or chitin (Yalpani, 1988, pg. 389), this yields a colloidal processed form of polysaccharide featuring high porosity and enhanced susceptibility to chemical reactions. Generation of "microfibrillated" cellulose or chitin is another example of a pretreatment procedure which produces enhanced surface area, increased water retention capacity and enhanced chemical acces¬ sibility (Yalpani, 1988, pg. 390) . Use of strong (> 1 8% ) sodium hydroxide is still another recognized pretreatment, or activa¬ tion, procedure found to be helpful as a starting point for preparing chemical derivatives of polysaccharides (Yalpani, 1988 , pg. 214) . (b)(1) . Deacetylation of Naturally Occurring Polysaccharides A variety of polysaccharides have been identified which are rich in N-acetylated residues. Upon chemical deacetylation these carbohydrates yield high molecular weight derivatives bearing primary amine groups directly linked to sugar carbons, that is, no sidearm spacer units present. (i) Chitosan. This is the dcacylated form of chitin. As des¬ cribed in the Merck Index (Budavari and coworkers, 1989, pg. 316) chitin is a colluloso-liko biopolymer the composition of which consists mostly of N-acctyl-D-glucosamine residues co- valvently linked by bota-1,4 bonds. Chemical deacylation re¬ moves acetate, generating primary amine groups still covalently bound to the polysaccharide. Chitosan has recognized uses in water treatment, in photographic emulsions, and in improving the dyability of synthetic fabrics and fibers. Tho free αmine groups in this substance also give it chelating properties (Austin and coworkers, 1981) . (ii) Chondroitin sulfate. This is a mucopolysaccharide found commonly in mammalian tissue. It consists of repeating disac- charide units, each of which has a D-glucuronic acid residue beta-1,4 linked to an N-acetylchondrosine residue (Merck Index, Budavari and coworkers, 1989, pg. 344) . (iii) Hyaluronic acid. This mucopolysaccharide is also found commonly in mammalian tissues. It consists of glucuronic acid and qlucosamine residues bound bv bcta-1,3 and beta-1,4 linkages (Merck Index, Budavari and coworkers, 1989, pp. 751-752) . (iv) Keratan sulfate. This mammalian glycosaminoglycan consists of α repeating disaccharido unit of a C-6 sulfatod C-2 N-acetyl- ated sugar residue and a galactose residue linked by beta-1,4 bonds (Yalpani, 1988, pp. 27-28) . (b)(2) . Chemical Amination of Polysaccharides (i) 2-Amino-2-deoxy-csllulose . Cellulose can bo αminatod by a process of selective oxidation, oximation and subsequent reduc¬ tion with lithium aluminum hydride (Yalpani, 1988, pp. 281-282) . (ii) Alternative amination procedures. Aminodcoxy polysacchar¬ ides can also bo prepared via azide or hydrazido intermediates or by reductive amination using sodium cyanoborohydridc (Yal¬ pani, 1988, pg. 281) . Besides being applied to cellulose, other non-digestible polysaccharides such as curdlan (Yalpani, 1988, pg. 22) may bo aminated by such chemical procedures. (iii) 3-Aminopropylcellulose. Reaction of cyanoethylcellulose with boranε-tetrahydrofuran or borane-dimethyl sulfide complexes in tctrahydrofuran generates 3-aminopropylccllulose (Yalpani, 1988, pgs. 250 and 255) . In this derivative each primary amine group is at the end of a three carbon sidcarm. ( iv) Aminoethylcellulose. This chemical has been previously marketed as an anion exchange column chromatography resin (Sigma Chemical Co. catalog, Feb. 1981) and used as such in protein purification studies (Fasold, 1975, pp 481-482) . (v) Other aminoalkyl-, amino(hydroxyalkyl )- , aminoalkyl-ethor-, and amino(hydroxyalkyl )-ether- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates. Noting that the chemical methodology for producing such deriva¬ tives is documented in public domain literature, the biomedical application of such derivatives for therapeutic purposes des¬ cribed herein is also claimed. This would include: aminoalkyl derivatives of the formula H 2 N-(CH 2 ) n -[carbohydrate] where n = 1 - 10, including alkyl isomers ; αmino(hydroxyalkyl ) - derivatives derivatives of tho formula H 2 N-(CH 2 ) B -CHOH-(CH 2 ) n -[carbohydrate] , where m = 0 - 10 n = 0 - 10; aminoalkyl-cther- derivatives of the formula H 2 N-(CH 2 ) n -0-[carbohydrate] , where n = 1 - 10; and amino(hydroxyaklyl )-ether- derivatives of the formula H 2 N-(CH 2 ) B -CHOH-(CH 2 ) n -0-[carbohydrate] , where m = 0 - 10 n = 0 - 10 (vi) Aminobenzyl- derivatives of cellulose, chitin or other naturally occurring non-digestible carbohydrates. As the aro¬ matic amine group is a weaker base than its aliphatic counter¬ part , this class of non-absorbable amines should be less chem¬ ically active than amino- and aminoalkyl- derivatives described above. These derivatives are of the following general structures : H 2 N-C 6 H f(CH 2 ) n -[carbohydrate] ; H 2 N-CH 2 -C 6 H 4 -(CH 2 ) n -[carbohydrate] ; H 2 N-C 6 H 4 -(CH 2 ) n -0-[carbohydrate] where n = 0 - 10; and H 2 N-C 6 H 4 -(CH 2 ) a -CHOH-(CH 2 ) n ~0-[carbohydrate] where m = 0 - 10 n = 0 - 10 This includes p-, o- and m-benzene ring amino- and aminomethyl- isomers, and alkyl group isomers. (vii) guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring non-absorbable carbo¬ hydrates selected from the group consisting of: H2N-C(=NH)-[carbohydrate] ; n ~[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H^T-C(=NH)-0-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H2N-C(=NH)-NH-[carbohydrate] ; H^ϊ-C(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H^-C(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof ; carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H^I-NHC(=NH)-NH-[carbohydrate] ; H^ϊ-NHC(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H 2 N-NHC(=NH)-N=CH-(CH ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H ϊ-NHC(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H ϊ-C(=NH)-NH-NH-[carbohydrate] ; H^ϊ-C(=NH)-NH-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof ; H^Ϊ-C(=NH)-NH-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^-C(=NH)-NH-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; and H 2 N-C(=NH)-NH-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof (b)(3). Aminatcd Sucrose Polyesters Mixtures of fatty acid hexa-, hepta- and octaesters of sucrose, known as sucrose polyester, are not hydrolyzed by pancreatic lipase enzymes and are not absorbed in the intestine (Jandacok, 1984). It is proposed and claimed herein that primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters may be of benefit in reduction of dietary carbonyl substances, analogous to the proposed action of other non-absorbable agents described herein. Such derivatives of sucrose polyesters would include structures in which the carbonyl trapping functional group is in the omega-, omega-1 or other isomeric position(s) within tho fatty acyl chains, fatty acyl chains having more than one nitrogen functional group and fatty acyl chains having hydroxyl groups. Such aminated sucrose polyesters may be used in pure form as a dietary supplement, or may be prepared as a coating on a particulate carrier such as cellulose or styrone divinylbenzene copolymer resin. (c) . Synthetic Polyamine Polymers (c)(1) . Synthetic polysaccharides consisting partly or entirely of aminosugars bound by bota-1,2, beta-1,3, beta-1,4 and/or beta-1,6 linkages may be regarded as non-absorbable potential carbonyl trapping agents. (c)(2) . Mixed polysaccharide polymeric derivatives. Primary αmine, aminoalkyl (one to ten carbons per alkyl group), αmino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group), aminoguanidine, aminoguani- dinyl-alkyl (one to ten carbons per alkyl group), aminoalkyl- guanidinyl (one to ten carbons per alkyl group), guanidine, aminobenzene and aminoalkylbenzcne (one to ten carbons per alkyl group) functional groups may be covalently attached to matrices such as epi-chlorohydrin copolymers of cellulose or chitin. Functional group spacer groups may include alkene as well as alkyl groups. (c)(3). Non-polysaccharidc polymeric derivatives. Primary amino, aminoalkyl (one to ton carbons per alkyl group), αmino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group) , aminoguanidine, aminoguani- dinylalkyl (one to ten carbons per alkyl group), aminoalkyl- guanidinyl (one to ten carbons per alkyl group), guanidine, aminobenzene and aminoalkylbenzcne (one to ten carbons per alkyl group) functional groups may be covalently attached to a wide variety of synthetic non-digestible polymers. Functional group spacer groups may include alkene as well as alkyl groups. Like their sugar-based counterparts, these agents should be capable of reacting with dietary carbonyl compounds. Nitrogen-contain¬ ing functional groups may be covalently attached to synthetic supports such as polystyrene, styrenε-divinylbenzene copolymer, polyvinyl alcohol and crosslinked derivatives thereof. (v) Co-Administration of Antioxidants and Lipid Peroxidation Inhibitors It is claimed that the therapeutic value of the primary agents described herein may bo maximized by administration in conjunc¬ tion with recognized antioxidant free radical trapping compounds such as vitamin E (Ξtuckoy, 1968, pp. 214-215) or other agents previously recognized as adjunts which facilitate in vivo capa¬ bility to inhibit lipid peroxidation, such as selenium (Stuckey, 1968, pg. 236) . Citric acid may also be included in this cate¬ gory of co-administered agents, as it is recognized as having antioxidant properties (Budavari and coworkers, 1989, pg. 363). This agent is also recognized as an inhibitor of Maillard reac¬ tions (Stuckey, 1968, pg. 210) . In a published list of agents which function to supplement the chain-breaking antioxidant property of vitamin E, Tappcl (1970, pg. 1138) mentioned ubiquinol, seleno-amino acids and sulfhydryl compounds (such as, glutathiono, sulfhydryl proteins and methionine) . Butylated- hydroxytolucnc (Frankel, 1987, pg. 81) and beta-carotcnc (Frankel, 1987, pg. 82) should also bo included in this group. (vi) Prophylactic Vitamin Co-Administration It is yet still another object of this invention that the safety and effectiveness of the products described herein may be opti¬ mized by co-administration of vitamins and derivatives thereof which may be inadvertently depleted by the therapeutic treatment of this invention or by the etiology of tho disease being ad¬ dressed, such as vitamin A (retinol), vitamin A aldehyde (retinal) , vitamin A acid (rotinoic acid), vitamin B * (thi- amino) , vitamin B 2 (riboflavin) , vitamin B g (pyridoxinc) , vitamin B 12 (cyanocobalamin) , vitamin D 2 , vitamin D 3 , vitamin H (biotin), vitamin K 1f vitamin K, oxide, vitamin(s) K 2 , vitamin K 5 and vitamin K g , vitamin K 7 , vitamin K-S(II), vitamin L^ vitamin L 2 , vitamin U, alpha-carotene, beta-carotcnc, gamma-carotene, omega- carotene, carnitine (vitamin By), folic acid (vitamin Be), folinic acid, niacinamide, nicotinic acid, pantothenic acid, pyridoxal, pyridoxal 5-phosphatε, and pyridoxamine. (vii) Co-Administration of Metabolites at Risk of Depletion It is another object of this invention that the safety and effectiveness of the products described herein may be optimized by co-administration of other metabolites, such as glycine, which may be depleted within the body during long term drug use. As many of the absorbable amine drugs described heroin are excreted from the body as glycine conjugates, co-administration of glycine may be advisable. Coonzymo A is a roguirod cof ctor for hippuricase, the liver enzyme which adds glycine to benzoic acid derivatives. Activity of hippuricase in glycinating some of the absorbable carbonyl-trapping drugs described herein may sequester a disproportionate fraction of the endogenous coonzymo A pool. Hence co-administration of pantothenic acid, a metabolic precursor of coenzymc A, may also serve to optimize the therapeutic procedures described herein. (viii) Co-Administration of Sulfhydryl Agents Noting the well documented ability of carbonyl agents to react with sulfhydryl groups (Jellum and coworkers, 1973), it is a further object of this invention that methionine and homo- cysteine may also be of clinical benefit as absorbable drugs capable of covalently binding aldehyde or ketone agents. It is also claimed that these drugs can be used most effectively when administered in conjunction with absorbable and non-absorbable amino and amine-related drugs described herein. Homocystcinc contains a froo sulfhydryl group. Methionine is converted in vivo to homocysteine by several enzymatic reactions which remove a methyl group. Thioctic acid, also known as alpha-lipoic acid, is also included in this category, as its structure includes a disulfidc group. This agent, a recognized growth factor (Buda¬ vari and coworkers, 1989, pg. 1469), may tend to be depleted in the tissues of patients having chronic inflammatory diseases involving etiologies which include dysfunction of aldehyde and/or ketone metabolism. The ability of acetaldchydc to com¬ bine with thioctic acid, thus deactivating it, has been reported (Smith, 1976, pg. 195). Hence the inclusion of thioctic acid in pharmaceutical preparations such as those described herein may be of clinical benefit. ( ix) Factors Affecting Dialy Dosage Schedule A daily protocol of amine and amine-related drug consumption, in combination with co-agents defined herein, may bo defined such that drug products are administered in timed-release and/or color coded tablets or capsules, so as to facilitate patient compliance and maximize therapeutic value. (4) Therapeutic Utilization Although their primary etiologies remain to be determined, prior art information indicates that the secondary ctiological proces¬ ses of degenerative diseases such as rheumatoid αrtritis de¬ pends, in part, on chronic inflammation. In addition, evidence of increased lipid peroxidation has been demonstrated in studios on muscular dystrophy and multiple sclerosis (Halliwell and Gutteridge, 1985, pg. 125) . Two examples may serve to illustrate the practical application of this invention. Example One: Pearson and Shaw (1982, pg. 299) described the following summary of an arthritis patient taking vitamin E and vitamin A: The correct dose of antioxidants for effective arthritis therapy must be determined by experi¬ mentation. The effective dose may be quite high. For example, a friend of ours who is a well-known artist in his fifties developed arthritis in his hands. This man's hands became so painful and stiff he could no longer use his fingers to remove tho caps from his tubes of paint. Ho tried vitamin E at increasing dose levels. It was not until he got up to 10,000 I.U. of E and 20,000 I.U. of A per day that he obtained relief from the pain and crip¬ pling stiffness. His hands are now flexible and can be used to draw without difficulty. But they remain so only as long as our friend takes 10,000 I.U. of E and 20,000 I.U. of A a day, not less (he's tried). This dosage of vitamin E far exceeds presently accepted levels of daily usage, which are generally regarded as being in the range of 400 I.U. per day. This particular combination of vita¬ mins E and A, both lipophilic, would not be expected to inhibit any of the free radical reactions taking place in agueous micro- environments. Nor would it chemically bind and thus deactivate any reactive aldehydes generated by the inflammatory process, as such aldehydes arc water soluble. Example Two: Patient L.S. has a history of arthritis dating back to a serious automobile accident in 1980. By January of 1991 she had serious arthritic involvement of the lumbar spine and chronic hip and knee joint pain on a continuous basis. She had difficulty raising herself from a chair, reguircd the assistance of a cane for activities as simple as walking from her front door to her car, was no longer able to go up or down a flight of stairs, and required use of a prescription analgesic drug every two hours during the night to sleep. She had participated in a program at the Pain Clinic of the University of Miami Medical School and at doctor's advice had used prescription drugs which included Clinoril (R) and Anaprox (R) , both non-steroidal anti- inflammatory agents. At tho recommendation of this inventor, patient L.S. began taking 800 I.U. vitamin E, 1. gm of methio¬ nine and 1.1 gm PABA per day for two months. Subseguently, vitamin E and methionine usage remained the same and PABA usage was increased to 2.2 gm per day, with the protocol continued on an indefinite basis. When previously examined by an orthopedics physician a diagnosis was established which included: ...Lumbar spine X-Rays in AP and lateral views show extensive degenerative arthritic changes at multiple levels of the lumbar spine...severe arthritic changes lumbar spine. Bursitis left greater trochanter clin¬ ically...She will always have a problem related to her underlying degenerative disease involving her lower back...She is favoring her left leg...Her straight leg raising is limited on the left side... Ten weeks after after initiating this inventor's PABA/vitamin E/ methionine protocol, patient L.S. reported that her αrthitis- relatcd pain was much decreased and her functional status much improved. By four months into use of this therapeutic protocol patient L.S. had stopped using her cane, had a walking gait which was much improved, had taken to raking leaves in the yard as a form of exercise, and no longer required nighttime analgesics to sleep. At twelve months on this protocol, patient L. S. reported climbing and descending a flight of stairs with¬ out difficulty, and her ability to climb stairs has continued to improve. When re-examined by her orthopedics physician seven months after beginning therapy, who was not informed of her use of the PABA/vitamin E/methionine protocol, tho doctor noted, in part : This patient is markedly better. She has normal straight leg raising. She has no significant leg pain. She walks well on her toes and walks well on her heels now without any evidence of motor weakness. There is no limp present. Unaware of the patient's collaborative effort with this inven¬ tor, the orthopedics physician was unable to provide an explan¬ ation of tho marked improvement in tho clinical status of patient L.S. At her office visit patient L. S. noted that she had stopped taking Anaprox, which her orthopedics physician had prescribed seven months earlier. This inventor recognizes the novel and original composition of primary amine and amine-related bonzoic acid derivatives as primary agents to be used with known antioxidant free radical trapping or inhibiting co-agents and not including vitamin C beyond its United States recommended daily allowance as a type of composition likely to have increased, synergistic properties for the treatment of chronic inflammatory diseases. This inventive strategy and the compositions thereof for clinical treatment of these diseases has not been previously recognized. PABA, many of the other αmine and amine-related primary agents, as well as the antioxidant free radical trapping co-agents arc chemicals which have been previously synthesized and described. Yet the present invention recognizes a new and novel combination of therapeutic properties, never recognized previously by people trained in this field, and the clinical applications thereof. This invention constitutes α significant and practical advance- ment of the clinical therapeutic technology available for treat¬ ing chronic inflammatory diseases. Without further elaboration the foregoing will so fully illus¬ trate my invention that others may, by applying current or fu¬ ture knowledge, adapt the same for use under various conditions of service. References Cited Ahnfelt-Ronne, I et_ al . "Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid" Gastroenteroloσv 98:1162-1169 (1990) Austin, PR et_ al_. "Chitin: New facets of research" Science 212:749-753 (1981) Baltes, W "Application of pyrolytic methods in food chemistry" J. Anal. Appl. Pyrol. 8:533-545 (1985) Bencdctti , A c_t_ al_. "Foot-edema induced by carbonyl compounds originating from the peroxidation of liver microsomal lipids" Biochem. Pharmacol. 29:121-124 (1980) Bingham, S and Cummings, JH "The use of 4-aminobcnzoic acid as a marker to validate tho completeness of 24 h urine collections in man" Clin. Sci. 64:629-635 (1983) Borne, RF ct al . "Anti-inflammatory activity of para-substituted N-benzenesulfonyl derivatives of anthranilic acid" J. Pharm. Sci . 63:615-617 (1974) Brooks, PM and Schwarzcr , AC "Combination chemotherapy in rheumatoid arthritis" Ann. Rheum. Pis. 50:507-509 (1991) Budavari, S, ed. Merck Index, 11th ed. , (Rahway, NJ, Merck & Co. , 1989) Carden, MJ et al . "2 , 5-Hexancdionc neuropathy is associated with the covalent crosslinking of ncurofilamcnt proteins" Neurochem. Pathol . 5:25-35 (1986) Chio, KS and Tappel, AL "Synthesis and characterization of the fluorescent products derived from malonaldehyde and amino acids" Biochemistry 8:2821-2827 (1969) Chojkicr, M e_t al_. "Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts" J. Biol. Chem. 264:16957-16962 (1989) Del Maestro, RF "An approach to free radicals in medicine and biology" Acta Physiol. cand. Suppl. 492:153-168 (1980) Domopoulos, HB "Control of free radicals in biologic systems" Fed. Proc. 32(8) : 1903-1908 (.1973) Domopoulos, HB ct al . "The free radical pathology and the micro- circulation in the major central nervous system disorders" Acta Physiol. Scand. Suppl. 492:91-119 (1980) Deutsche Gold- und Silbcr-Scheidcanstalt vor . Rocsslcr "Analgesic, antiinflammatory, and antipyretic p-aminobonzoic acid anilides" Chem. Abstr. 76:427 [abstract 140260d] (1972) Dowd, AL Physician's Desk Reference, 47th ed. (Montvale, NJ, Medical Economics Data, 1993) Draper, HH _ot_ a _. "The metabolism of malondialdehyde" ipjds 21:305-307 (1986) Drug Information for the Health Care Professional, 8th ed. (Rockvillc, MD, United States Pharmacopcial Convention, 1988) pgs. 111-113 Dull, BJ ct al . "5-Aminosalicylate: oxidation by activated leukocytes and protection of cultured cells from oxidative damage" Biochem. Pharmacol. 36:2467-2472 (1987) Dunlop, AP and Peters, FN Tho Furans (New York, Reinhold Publishing, 1953) Fasold, H "Chromatography of proteins" in Chromatography: A Laboratory Handbook of Chromatographic and Electrophoretic Method , 3rd ed. , Hoffmann, E, ed. (New York, Van Nostrand Reinhold, 1975) pp. 466-526 Feeney, RE et al . "Carbonyl-amine reactions in protein chemistry" Adv. Protein Chem. 29:135-203 (1975) Flood, JF et al . "Two-drug combinations of memory enhancers: effect of dose ratio upon potency and therapeutic window, in mice" Life Sci. 42:2145-2154 (1988) Frankel, EN "Secondary products of lipid oxidation" Chem. Phys . ipids 44:73-85 (1987) Ghose, A et al . "Protection with combinations of hydroxytrypto- phan and some thiol compounds against whole-body gamma irradi¬ ation" Int. .7. Radiat. Biol. 44:175-181 (1983) Goldstein, M et al . "The antiparkinsonian activity of dopamino agonists and their interaction with central dopaminc receptor subtypes" Adv. Neurol. 53:101-106 (1990) Gougerot , MM and Hewitt, J ["Scleroderma in patches, combined action of para-aminobenzoic acid and of alpha-tocopherol" ] Bull . Soc. Fr. Derma o1. Syph■ 58:42-43 (1951) Groσtveld, M and Halliwell, B "2 , 3-Dihydroxybcnzoic acid is a product of human aspirin metabolism" Biochem. Pharmacol. 37:271- 280 (1988) Gutteridge, JM and Wilkins, S "Copper-dependent hydroxyl radical damage to ascorbic acid. Formation of a thiobarbitu i e.cid- rcactive product" FEES Lett. 137:327-330 (1982) Hall, ED "Beneficial effects of the 21-aminostcroid U74006F in acute CNS trauma and hypovolemic shock" Acta Anaesth. Belg. 38:421-425 (1987) Halliwell, B and Gutteridge, JM "The importance of free radicals and catalytic metal ions in human diseases" Molec. Aspects Med. 8:89-193 (1985) Higson, FK ct al . "Iron enhancement of ascorbatc toxicity" Free Rad. Res . Comms. 5:107-115 (1988) Holdren, RF and Hixon, RM "The reaction of 2-methylfuran with formaldehyde and substituted ammonium chlorides" J. Am. Chem. Soc. 68:1198-1200 (1946) Howie, MB and Bourkc, E "Metabolism of p-aminobenzoic acid in the perfused livers of chronically uraomic rats" Clin. Sci . 56:9-14 (1979) Huff, BB, ed. , Physicians' Desk Reference, 34th ed. (Oradell, NJ, Medical Economics Co. , 1980) Hunter, MI et al . "Lipid peroxidation products and antioxidant proteins in plasma and cercbrospinal fluid from multiple sclerosis patients" Neurochem. Res. 10:1645-1652 (1985) Jackson, MJ et al . "Techniques for studying free radical damage in muscular dystrophy" Med. Biol . 62:135-138 (1984) Jandacck, RJ "Studies with sucrose polyester" Int. J. Obes . 8(suppl. 1) : 13-21 (1984) Jcllum, E et al . "The presence of furan derivatives in patients receiving fructose-containing solutions intravenously" Clin. Chim. Actα 47:191-201 (1973) Kar, NC and Pearson, CM "Catalasc, supcroxide dismutase, gluta- thione reductase and thiobarbituric acid-reactive products in normal and dystrophic human muscle" Clin. Chim. Actα 94:277-280 ( 1979) Katsnelson, BA et al . "Trends and perspectives of the biological prophylaxis of silicosis" Environ. Health Pcrspcct . 82:311-321 ( 1989) Konccki , J et al . "Histochcmical changes in the small intestine in acute furfural poisoning" Folia Histochem. Cytochcm. 12:59-66 ( 1974) Kontos , HA et al . "Prostaglandinε in physiological and in certain pathological responses of the cerebral circulation" Fed. Proc. 40:2326-2330 (1981) Kostyuk, VA ct al ; . [ "Antioxidativc activity of the anti- arthritic drugs"] Vopr . Med. Khim. 36(3) :37-39 (1990) Kurdin, AN ["Free radical lipid oxidation in the pathogenesis of myocardial inf: rction" ] Kardiologia 18:115-118 (1978) Kushner, I, ed. Understanding Arthritis (New York, Charles Scribner's Sons, 1984) Lever, M ct al . "Automated fluorimctric determination of furfurals" Anal. Biochem. 144:6-14 (1985) Maksimov, OB and Rebachuk, NM ["Screening for the presence of antioxidants in plant extracts"] Rastit. Resur . 21 ( 2 ) : 216-220 ( 1985) Mel'nikova, TA and Ryzhova,AF "Effect of p-aminobenzoic acid on the course of experimental myocardial infarction" translated from Byulleten Eksperimcntal 'noi Biologii i Meditsiny 63(4) :61- 64 (1967) Nakkcn, KF "The action of X-rays on dilute solutions of p-amino- bonzoic acid" Radiation Res. 21:446-461 (1964) Nakkon, KF and Pihl , A "Tho X-ray-induced damage to the p-amino¬ benzoic acid moiety of folic acid and some other p-aminobenzoic acid conjugates irradiated in solution" Radiation Res . 27:19-31 ( 1966) Olney, JM et aj_, "L-Cysteine , a bicarbσnate-scnsi tive endogenous excitotoxin" Science 248:596-599 (1990) Ortwcrth, BJ and Olcscn, PR "Ascorbic acid-induced crosslinking of lens proteins: evidence supporting α Mαillard reaction" Biochim. Biophys. Acta 956:10-22 (1988) Passwater, RA The Antioxidants. The Nutrients that Guard the Body Against Cancer, Heart Disease, Arthritis and Allergies - and Even Slow the Aging Process (New Canaan, CT, Keats Publishing, 1985) Pearson, D and Shaw, S Life Extension. A Practical Scientific Approach (New York, Warner Books, 1982) Peppercorn, MA "Sulfasalazinc: Pharmacology, clinbical use, toxicity, and related now drug development" Ann. Intern. Med. 101:377-386 (1984) Pcttersen, JE and Jellum, E "The identification and metabolic origin of 2-furoylglycine and 2 , 5-furandicarboxylic αcid in human urine" Clin. Chim. Acta 41:199-207 (1972) Priestley, GC and Brown, JC "Effects of potassium para-amino- bonzoate on growth and macromolecule synthesis in fibroblasts cultured from normal and sclcrodermatous human skin, and rheumatoid synovial cells" J. Invest. Dermatol . 72:161-164 (1979) Pryor , WA ct al . "Autoxidation of polyunsaturatcd fatty acids. Part 1. Effect of ozone on the autoxidation of neat methyl linoleate and methyl linolenato" Arch. Environ. Health 31:201- 210 (1976) Repine, JE ct al . "Generation of hydroxyl radical by enzymes, chemicals, and human phagocytes in vitro. Detection with the anti-inflammatory agent, dimethyl sulfoxide" J. Clin. Invest. 64:1642-1651 (1979) Rice, EW "Furfural: exogenous precursor of certain urinary furans and possible toxicologic agent in humans" Clin. Chem. 18:1550-1551 (1972) Richmond, R et al . "Superoxide-dcpendent formation of hydroxyl radicals: detection of hydroxyl radicals by the hydroxylation of aromatic compounds" Anal. Biochem. 118:328-335 (1981) Rinne, UK "New strategies in tho treatment of early Parkinson's disease" Acta Neurol . Scand . 8 (suppl. 136) :95-98 (1991) Rowley, .D ct al . "Lipid peroxidation in rheumatoid arthritis: thiobarbituric acid-rcactivc material and catalytic iron salts in synovial fluid from rheumatoid patients" Clin. Sci . 66:691- 695 (1984) sawicki, E et al . "Comparison of spectrophotometric and spectro- photofluorometric methods for tho determination of malanaldo- hyde" Anal. Chem. 35:199-205 (1963) Schaucnstein, E and Esterbaucr, H Aldehydes in Biological Systems. Their Natural Occurrence and Biological Activities (London, Piσn Limited, 1977) Scott, CC and Robbins, SB "Toxicity of p-aminobenzoic acid" Proc. Soc. E p. Biol . Med. 49:184-186 (3942) Scott, G "Antioxidants: Radical chain-breaking mechanisms" in Atmospheric Oxidation and Antioxidants (New York, Elsevier Publishing Co., 1965) Shimada, 0 and Yasuda, H "Lipid peroxidation and its inhibition by tinoridine. II. Ascorbic αcid-induced lipid peroxidation of rat liver mitochondria" Piochim. Biophys. Acta 572:531-536 ( 1979) Shimizu, J and Watanabc, M "Gas chromatographic analysis of furfural and hydroxymothyl-furfural in wine" Agric. Biol. Chem. 43:1365-1366 (1979) Sigma Chemical Co. catalog, Feb. 1981 (Saint Louis) Sigma Chemical Co. catalog, 1993 (Saint Louis) Slight, SH ct al . "Glycation of lens proteins by the oxidation products of ascorbic acid" Biochim. Biophys. Acta 1038:367-374 ( 1990) Smith, WT "Nutritional deficiencies and disorders" in Greenfield's Neurology, Blackwood, W and Corsellis, JAN, eds . (Chicago, Year Book Medical Publishers, 1976) pp. 194-237 Stuckey, BN "Antioxidants as food stabilizers" in CRC Handbook of Food Additives, Furiα, TE, od. (West Palm Beach, FL, CRC Press, 1968) Tappel, AL "Biological antioxidant protection against lipid per¬ oxidation damage" Am. J. Clin. Nutr . 23:1137-1139 (1970) Thiele, K "p-Aminobonzoic acid anilidos" Chem. Abstr . 75:462 [abstract 35466g] (1971) Toufexis, A "The new scoop on vitamins" Time 139( 14 ) :54-59 (1992) Ulbricht, RJ ct al . "A rev ew of 5-hydroxymcthγlfurfural (HMF) in parenteral solutions" Exp. AppI . Toxicol. 4:843-853 (1984) Warner-Lambert Co. , United States Patent No. 5,002,703, "Benzoic acid and benzoic acid ester derivatives having antiinflammatory and analgesic activity," issued 8/25/87 Wcissmann, G "Aspirin" Scientific American 264:84-90 (1991) Weizman, Z ct_ al . "Bentiromide test for assessing pancreatic dysfunction using analysis of para-aminobenzoic acid in plasma and urine" Gastroonterology 89:596-604 (1985) Winitz, M et al . "Studies in metabolic nutrition employing chem¬ ically defined diets. I. Extended feeding of normal human adult males" Am. J. Clin. Nutr . 23:525-545 (1970) Wong, SF ct al . "The role of supcroxidc and hydroxyl radicals in the degradation of hyaluronic acid induced by metal ions and by ascorbic acid" J. Inorg. Biochem. 14:127-134 (1981) Yalpani , M Polysaccharides: Syntheses, Modifications and Structure-Property Relations (Now York, Elsevier, 1988) Young, DS et al . "Influence of α chemically defined diet on tho composition of serum and urine" Clin. Chem. 17:765-773 (1971) Zarafonctis, CD "Clinical use of para-aminobenzoic acid" Texas State J. Mod. 49:666-672 (1953) Zarafonetis, CJ "Antifibrotic therapy with Potaba" Am. J. Med. Sci . 248:550-561 (1964) Zarafonetis, CJ ct al . "Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival" J. Clin. Epidemiol . 41:193-205 (1988) Zivin, JA and Choi, DW "Stroke therapy" Sci . Am. 265:56-63 ( 1991) Zuckcrman, JE et_ al . "Evaluation of antifibrotic drugs in blcomycin-induced pulmonary fibrosis in hamsters" J. Pharmacol. Exp. Ther. 213:425-431 (1980)

Claims: I c laim : 1 . Use of a composition comprising a therapeutically effective amount of a primary agent and at least one co-agont, said primary agent comprising a water soluble, low molecular weight primary αmine or amine-related derivative of benzoic acid in the molecular weight range of 100 to 1,400, for use in the treatment of symptoms of chronic inflammatory disorders featuring pathol¬ ogy based in part on increased lipid peroxidation, wherein said primary and co-agont combination produces an anti-inflammatory and analgesic effect. 2. Use of a composition comprising a therapeutically effective amount of a primary agent and at least one co-agent for treat¬ ment of the symptomology of a chronic inflammatory disease, wherein the chronic inflammatory disease is characterized in part by the deterioration of intracellular and extracellular structures and is characterized by tho spurious pathological chemical covalent bond crosslinking of said structures, forma¬ tion of pathological addition products of said structures, or chemical cleavage products of said structures, said deteriora¬ tion resulting from reaction of inflammation site structures in the human with disease-induced carbonyl-containing aliphatic and aromatic hydrocarbons resulting from increased lipid peroxida¬ tion associated with chronic inflammation. 3. The use of Claim 1 characterized in that the primary agent has at least one primary amine group or amine-related group thereon for reaction with lipid peroxidation product carbonyl groups to decrease the deterioration of said intracellular and extracellular structures and to decrease the spurious pathologi¬ cal chemical crosslinking, other derivation or cleavage of said structures by permitting said primary agent to effectively com¬ pete with and covalently bind to said disease-induced carbonyl- containing lipid peroxidation products. 4. The use of Claim 1 characterized in that the primary agent additionally does not interact with normal cell metabolism of said human or does so in α non-cytotoxic manner, and wherein said primary agent is readily absorbed by the kidney tissue of said human and excreted in the urine of said human without nephrotoxic consequences. 5. Use of Claim 1 characte ized in that the primary agent is a water soluble, low molecular weight substance (100 to 1,400 range of molecular weights) selected from the group consisting of the free αcid forms, salts, benzene ring isomers, amide derivatives, carboxylic acid ester derivatives and analogous non-αromatic benzene ring derivatives of the group consisting Of: oalkyl group having carbons including ocarbon isomers or hydroxylated vatives thereof -NHC(=NH)NH ? -(CH ? ) n NHC(=NH)NH ? where n = 1-10 -C(=NH)-NH, -(CH 2 ) n -CH=NC( =NH)NH ? whore n = 1-10 -NHC(=NH)NHNH, -(CH 2 ) n NHC( =NH)NHNH ? where n = 1-10 - (CH *_) n -CH=NC( =NH)NHNH, where n - 1-10 -NHNHC(=NH)NH 2 -(CH 2 ) n -NHNHC(=NH)NH 2 where n = 1-10 - (CH,) n -CH=N-NHC (= H)NH , where n = 1--10 R, - -NH, -aminoalkyl group ( 1-10 carbons ) including hydrocarbon -NHC(=NH)NHNH : (continued) - (CH ? ) n -CH=NC{ ^ NH)NHNH , where n = 1-10 -NHNHC(=NH)NH ? -(CH 2 ) n -NHNHC( =NH)NH, where n - 1-10 -(CH,) n -CH=N-NHC(=NH)NH 2 where n = 1-10 R, = -NH 2 -OH " -0-CH 3 -O-R' with alkyloxy group R' having 2-10 carbons including hydrocarbon isomers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof including hydrocarbon isomers and/or hydroxylated derivatives thereof = 0-10 s of roup eof -(CH 2 ) n -CH=NC(=NH)NH , where n = 1-10 -NHC( =NH)NHNH ? -(CH,) n NHC( =NH ' )NHNH, where n = 1-10 - (CH,) n -CH=NC(=NH)NHNH , where n = 1-10 -NHNHC( =NH)NH 2 -(CH,) n -NHNHC(=NH)NH, where n = 1-10 - (CH,) n --CH=N-NHC(=NH)NH 2 where n = 1-10 ( continued) R ? = -NH, -H -OH -O-CH, -O-R, where alkyloxy group R 3 has 2-10 carbons ' including hydrocarbon isomers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof -SO j H -CH., -(CH,) n CH,where n = 1-10 including hydrocarbon isomers and/or hydroxylated derivatives thereof R 1 = -H -CH, -0H J R" = -H -CH 3 -OH, for controlling the symptoms of disorders selected from the group consisting of chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbεstosis, silicosis, chronic obstruc¬ tive pulmonary disease, Lymc disease, inflammatory myopathies , status epilepticus, inflammatory neuropathies, myasthenia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and repcrfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. 6. The use of Claim 1 characterized in that said therapeutical¬ ly effective amount of said primary agent is a dosage in the range of one gram/day to 20 grams/day. 7. The use of Claim 1 characterized in that said therapeutical¬ ly effective amount of the primary agent is administered orally. 8. The use of Claim 1 characterized in that said therapeutical¬ ly effective amount of the primary agent is administered intravenously. 9. The use of Claim 1 characterized in that the co-agent is a non-absorbable polyamine substance or non-absorbable polyamine- related substance, α therapeutically effective amount of said co-agent acting to covalently bind to and sequester dietary carbonyl-containing products in said human for controlling the symptoms of disorders selected from the group consisting of chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstructive pulmonary disoasε, Lyme disease, inflammatory myopathies, status epilepticus, in¬ flammatory neuropathies, myasthenia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post-evεnt ischemia and roperfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. 10. The use of Claim 9 characterized in that the co-agent is a non-absorbable polyamine substance or non-absorbable polyamine- related substance selected from tho group consisting of: a. naturally occurring polysaccharides having bcta-1,2, bcta- 1,3, beta-1,4 and/or beta-1,6 linkages containing aminosugars including the chitin class of biopolymers having the general structure of poly-beta-( 1—>4)-N-acetγl-D-glucosamine, and bear¬ ing at least one free primary amino group; b. deacetylated naturally occurring polysaccharides , having at least one N-acetylatod residue, including chitosan, deacetylated chondroitin sulfate, or deacetylated hyaluronic acid; c. chemically aminatod polysaccharides selected from the group consisting of: αminodooxy polysaccharides such as 2-amino-2-deoxy- ecllulosc; aminoalkyl-, amino(hydroxyalkyl )- , aminoalkyl-cthcr- , and αmino(hydroxyalkyl ) -other- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates selected from tho group consisting of H 2 N-(CH 2 ) n -[carbohydrate] where n = 1-10, including alkyl isomers; H 2 N-(CH 2 ) β -CHOH-(CH 2 ) n -[carbohydrate] , where m = 0-10 and n = 0-10; H 2 N-(CH 2 ) n -0-[carbohydrate] where n = 1-10; H 2 N-(CH 2 ) ffl -CHOH-(CH 2 ) n -0-[carbohydrate] where m = 0-10 and n = 0-10; aminobcnzyl- derivatives of cellulose, chitin or other naturally occurring non-digestiblo carbohydrates selected from the group consisting of H 2 N-C 6 H 4 -(CH 2 ) n -[carbohydrate] , H 2 N-CH 2 -C 8 H 4 -(CH 2 ) n -1carbohydrate] , H2N-C 8 H 4 -(CH 2 ) n -0-[carbohydrate] where n = 0 - 10, and H 2 N-CgH 4 -(CH 2 ) i -CHOH-(CH 2 ) n -0-[carbohydrate] where m = 0-10 and n = 0-10, including p-, o- and m-benzene ring amino- isomers, aminomethyl- isomers and alkyl group isomers thereof ; guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring non-absorbable carbo¬ hydrates selected from the group consisting of: H2N-C(=NH)-[carbohydrate] ; n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-0-(CH 2 ) n -[carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers, ether linkage isomers and hydrox¬ ylated derivatives thereof; H p-C(=NH)-NH-[carbohydrate] ; H^I-C(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers and hydroxylated derivatives thereof ; H 2 N-C(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in- eluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H I-C(=NH)-N=CH-(CH 2 ) „-[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; H2N-C(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H j N-NHC(=NH)-NH-[carbohydrate] ; H^ϊ-NHC(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; H^ϊ-NHC(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, other linkage isomers and hydroxylated derivatives thereof; H^-NHC(=NH)-N=CH-(CH 2 ) „-[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H ϊ-C(=NH)-NH-NH-[carbohydrate] ; H2N-C(=NH)-NH-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^-C(=NH)-NH-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof ; carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; d. primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters having one or more carbonyl trapping func¬ tional group per molecule wherein each carbonyl trapping functional group is in the omega-, omcga-1 or other isomeric position within the fatty acyl chains, wherein each fatty αcyl chain may have from 3 to 26 carbons, from one to five nitrogen functional groups and from one to 24 hydroxyl groups; c . synthetic polysaccharides consisting partly or entirely of αminosugars bound by bota-1,2, betα-1,3, beta-1,4 αnd/or beta- 1 , 6 linkages; f. mixed polysaccharide polymeric derivatives wherin primary amine, aminoalkyl (one to ton carbons per alkyl group) , amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ten carbons per alkyl group) , aminoalkyl- guanidinyl (one to ten carbons per αlkyl group) , guanidine, aminobenzene and/or aminoalkylbenzcne (one to ten carbons per αlkyl group) functional groups are covalently attached to matrices such as cpi-chlorohydrin copolymers of cellulose or chitin and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups; and g. non-polysaccharide polymeric derivatives wherein primary amine, aminoalkyl (one to ten carbons per alkyl group), aminohy- droxyalkyl (one to ton carbons per alkyl group and one to ton hydroxyl groups per alkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ton carbons per αlkyl group) , aminoalkyl- guanidinyl (one to ten carbons per alkyl group), guanidine, aminobenzene and/or aminoalkylbenzcne (onε to ten carbons per alkyl group) functional groups are covalently attached to a synthetic non-digestible polymer selected from the group consisting of polystyrene, styrcnc-divinylbcnzcnc copolymer, polyvinyl alcohol and crosslinkod derivatives thereof, and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups . 11. The use of Claim 9 characterized in that said co-agent is in a microfibrillated form or microcrystalline form having enhanced surface area, increased porosity, increased water retention capacity and enhanced chemical accessibility. 12. The use of Claim 9 characterized in that said therapauti- cally effective amount of said non-absorbable polyamine co-agent or non-αbsorbable polyamine-related co-αgent is administered orally. 13. The use of Claim 9 characterized in that said therapeuti¬ cally effective amount of said co-agent is a dosage in thr range of one gram/day to 40 grams/day. 14. The use of Claim 1 characterized in that at least one co- agent is selected from the group consisting of antioxidants and free radical trapping compounds, chemicals having indirect anti¬ oxidant properties, suspending reagents, vitamins and deriva¬ tives thereof, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulfhydryl containing chemicals for controlling tho symptoms of disorders selected from the group consisting of chronic gingivi¬ tis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestos!s, silicosis, chronic obstructive pulmonary disease, Lyme disease, inflammatory myopathies, status epilepticus, inflammatory neuropathies, myasthonia gravis, multiple sclerosis, as well as lessening of inflammatory site edema, and treatment of post- event ischemia and reperfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction. 15. The use of Claim 14 characterized in that said co-agont antioxidants and free radical trapping compounds are selected from the group consisting of vitamin E (alpha-tocophcrol ) , vitamin E acetate, vitamin E succinate, mixed tocophαrols, beta- carotcnc, vitamin A, butylatcd hydroxytolucnc, citric acid, ubiquinol , glutathiono, homocysteine and methionine. 16. The use of Claim 14 characterized in that said co-agents having indirect antioxidant properties arc selected from the group consisting of selenium and selono-containing αmino acids. 17. The use of Claim 14 characterized in that the co-agent sus- pending reagents are selected from the group consisting of carboxymethyl cellulose, microcrystalline cellulose, cellulose, starch, dicalcium phosphate, tricalcium phosphate, stearic acid, magnesium stearate, silica, soy flour, watercress, yeast, alfal¬ fa, parseley, lecithin, rice bran, gum tragacanth, gum guar , gum agar, gum arabic, gum carrageenan, gum ghatti, gum karaya, locust bean gum, gum mastic, gum mesquite and gum xanthan, and wherein suspending reagents may be compounded together with a primary agent and at least one co-agent so as to produce a slow release formula. 18. The use of Claim 14 characterized in that said vitamins are selected from the group consisting of vitamin A, vitamin A aldehyde (retinal), vitamin A acid (rεtinoic acid), vitamin B | (thiamine), vitamin B 2 (riboflavin) , vitamin B 6 (pyridoxine) , vitamin B 12 (cyanocobalamin) , vitamin D 2 , vitamin D 3 , vitamin H (biotin), vitamin K. . , vitamin K, oxide, vitamin(s) K 2 , vitamin K 5 and vitamin K 6 , vitamin K 7 , vitamin K-S(II), vitamin L,, vitamin L 2 , vitamin U, alpha-carotene, beta-carotene, gamma-carotene, omega-carotene, carnitine (vitamin B τ ) , folic acid (vitamin Be) , folinic acid, niacinamide, nicotinic acid, pantothenic acid, pyridoxal, pyridoxal 5-phosphate and pyridoxamine. 19. The use of Claim 14 characterized in that said chemical conjugating co-agents which facilitate kidney drug elimination are selected from the group consisting of glycine, derivatives of glycine, and pantothenic acid. 20. The use of Claim 14 characterized in that said metabolite at risk of depletion is selected from the group of co-agents consisting of pantothenic acid and derivatives thereof. 21. The use of Claim 14 characterized in that said co-agent is a sulfhydryl containing agent or derivative thereof such as homocysteine, methionine or thioctic acid (alpha-lipoic acid) . 22. The use of Claim 14 characterized in that said at least one 22. The use of Claim 14 characterized in that said at least one co-agent is administered orally. 23. The use of Claim 14 characterized in that said at least one co-αgont is administered intravenously. 24. Use of a composition for treating mammals suffering from a chronic inflammatory disorder featuring pathology which includes in part increased lipid peroxidation comprising orally or intra¬ venously administering a therapeutically effective amount of a primary therapeutic agent sufficient to treat said mammal for said mammalian disorder, in combination with at lsast one co- agent, wherein said mammalian disorder is selected from a group consisting of arthritis, inflammatory site edema, acute central nervous system trauma, stroke and myocardial infarction, wherein the primary thεrapeutic agent is selected from the group con¬ sisting of primary amine and amine-related benzoic acid deriva¬ tives which are water soluble and of molecular weight 100 to 1,400 as defined in Claim 5, wherein the primary agent acts by covalently binding to and sequestering carbonyl compounds which result from increased lipid peroxidation in said mammal, and wherein said primary agent is administered with at least one of said co-agents as defined in Claim 9 or Claim 14. 25. The use of Claim 24 characterized in that the primary agent is used in a dosage of from 10 mg/kg/day to 1.0 gm/kg/day. 26. The use of Claim 24 characterized in that the non-absorb¬ able polyamine substance or non-absorbable polyamine-related substance as defined in Claim 9 is usεd in a dosage of from 10 mg/kg/day to 1.0 gm/kg/day. 27. A pharmaceutical composition for use in the treatment of the symptoms of disorders selected from the group consisting of chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstructive pulmonary disease, Lyme disease, inflammatory myopathies, status epilepticus, inflammatory neuropathies, myasthcnia gravis, multiple sclero¬ sis, as well as lessening of inflammatory site edema, and treatment of post-event ischemia and reperfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction, the composition comprising a water soluble, low molecular weight primary agent (100 to 1,400 range of molecular weights) selected from the free acid forms, salts, benzene ring isomers, amide derivatives, carboxylic acid oster derivatives and analogous non-aromatic benzene ring derivatives of the group consisting of: oalkyl group having carbons including ocarbon isomers or hydroxylated derivatives thereof -NHC(=NH)NH 2 -(CH 2 ) n NHC(=NH)NH 2 where n = 1-10 -C(=NH)-NH, -(CH 2 ) n -CH=NC( =NH)NH 2 where n = 1-10 -NHC(=NH)NHNH , -(CH ? ) n NHC( =NH)NHNH 2 where n = 1-10 -(CH 2 ) n -CH=NC(=NH)NHNH 2 where n = 1-10 -NHNHC(=NH)NH, -(CH 2 ) n -NHNHC( =NH)NH 2 where n = 1-10 - (CH 2 ) n -CH=N-NHC(=NH)NH 2 where n = l-'-lO R . = -NH 2 -aminoalkyl group (1-10 carbons ) n -NHC(=NH)NHNH, -(CH 2 ) n NHC(=NH)NHNH, whore n = 1-10 -(CH 2 ) n -CH=NC(=NH)NHNH, where n = 1-10 -NHNHC(=NH)NH ? -(CH 2 ) n -NHNHC(=NH)NH 2 where n = 1-10 -(CH 2 ) n -CH=N-NHC(=NH)NH 2 where n = 3-10 R- -NH 1 -OH -0-CH 3 -O-R 1 with alkyloxy group R' having 2-10 carbons including hydrocarbon isomers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof including hydrocarbon isomers and/or hydroxylated derivatives thereof 10 -(CH 2 ) n -CH=NC(=NH)NH 2 where n = 3-30 -NHC( =NH)NHNH 2 -(CH ? ) n NHC( =NH)NHNH 2 where n = 1-10 - ( CH ,) n -CH=NC ( =NH ) NHNH , where n = 1 - 10 -NHNHC ( =NH ) NH 2 - ( CH ,) n -NHNHC ( =NH ) NH , where n = 1 - 10 - ( CH ,) n -CH=N-NHC ( =NH ) NH , where n = 1 -10 ( cont inued ) R 2 = -NH 2 -H -OH carbons inclu ing hydrocarbon isomers and/or hydroxylated derivatives thereof -aminoalkyl group (1-10 carbons) including hydrocarbon isomers and/or hydroxylated derivatives thereof inc uding hydrocarbon isomers and/or hydroxylated derivatives thereof R' = -H -CH, -OH 3 R" = -H - -CCH, -OH; in a dosage range of from one gram/day to 20 grams/day, in association with a pharmaceutically acceptable carrier thereof. 28. The composition of Claim 27 additionally comprising at least one co-agent. 29. A pharmaceutical composition for use in the treatment of tho symptoms of disorders selected from the group consisting of chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis, ileitis, colitis, interstitial cystitis, arthritis, tendinitis, carpel tunnel syndrome and other cumulative trauma disorders, systemic lupus erythematosus, autoimmune vasculitis, asbestosis, silicosis, chronic obstructive pulmonary disease, Lymo disease, inflammatory myopathies, status epilepticus, inflammatory neuropathies, myasthenia gravis, multiple sclero¬ sis, as well as lessoning of inflammatory site edema, and treatment of post-event ischemia and repcrfusion symptomology resulting from acute central nervous system trauma, stroke and myocardial infarction, the composition comprising one or more non-absorbable polyamine substance or non-absorbable polyamine-related substance selected from the group consisting of: a. naturally occurring polysaccharides having beta-1,2, beta- 1,3, beta-1,4 and/or beta-1 , 6 linkages containing aminosugars including the chitin class of biopolymers having tho general structure of poly-beta-( 1—»4)-N-acetyl-D-glucosa ine, and bear¬ ing at least one free primary amino group; b. deacetylated naturally occurring polysaccharides , having at least one N-acotylatod residue, including chitosan, doacαtylated chondroitin sulfate, or deacetylated hyaluronic acid; c. chemically aminatαd polysaccharides selected from the group consisting of: aminodeoxy polysaccharides such as 2-amino-2-dcoxy- collulose; aminoalkyl-, amino(hydroxyalkyl)-, aminoalkyl-ethcr- , and amino(hydroxyalkyl) -ether- derivatives of cellulose, chitin and other naturally occurring non-digestible carbohydrates selected from tho group consisting of H2 N-(CH 2 ) n -[carbohydrate] where n = 1-10, including alkyl isomers ; H 2 N-(CH 2 ) B -CHOH-(CH 2 ) n -[carbohydrate] , where m = 0-10 and n = 0-10; H 2 N-(CH 2 ) n -0-[carbohydrate] where n = 1-10; H 2 N-(CH 2 ) a -CHOH-(CH 2 ) n -0-tcarbohydrate] where m = 0-10 and n = 0-10; aminobenzyl- derivatives of cellulose, chitin or other naturally occurring non-digestiblo carbohydrates selected from the group consisting of H 2 N-C 6 H 4 -(CH 2 ) n -[carbohydrate] , H 2 N-CH 2 -C 6 H 4 -(CH 2 ) n -[carbohydrate] , H2N-Cg H 4 -(CH 2 ) n -0-[carbohydrate] where n = 0 - 10, and H 2 N-CgH 4 -(CH 2 ) n| -CHOH-(CH 2 ) n -0-[carbohydrate] where m = 0-10 and n = 0-10, including p- , o- and m-benzene ring aminoiso- mεrs , aminomεthyl- isomers and alkyl group isomers thereof; guanidine and aminoguanidine derivatives of cellulose, chitin or other naturally occurring non-absorbable carbo¬ hydrates selected from the group consisting of: H£I-C(=NH)-[carbohydrate] ; H^ϊ-C(=NH)-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H^ϊ-C(=NH)-0-(CH 2 ) n -[carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers, ether linkage isomers and hydrox¬ ylated derivatives thereof; H^ϊ-C(=NH)-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, includ¬ ing hydrocarbon isomers and hydroxylated derivatives thereof; H2N-C(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; „-[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H^I-C(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, in¬ cluding hydrocarbon isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-NH-[carbohydrate] ; H j N-NHC(=NH)-NH-(CH 2 ) n ~[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-NH-(CH 2 ) n -0-[carbohydrate] , where n= 1-10, in¬ cluding hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; H^ϊ-NHC(=NH)-N=CH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H2N-NHC(=NH)-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; -NH-NH-[carbohydrate] ; H2N-C(=NH)-NH-NH-(CH 2 ) n -[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated derivatives thereof; H 2 N-C(=NH)-NH-NH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; „-[carbohydrate] , where n = 1-10, including hydrocarbon isomers and hydroxylated-derivatives thereof; H^I-C(=NH)-NH-N=CH-(CH 2 ) n -0-[carbohydrate] , where n = 1-10, including hydrocarbon isomers, ether linkage isomers and hydroxylated derivatives thereof; d. primary amine, aminoguanidine and guanidine derivatives of sucrose polyesters having one or more carbonyl trapping func¬ tional group per molecule wherein each carbonyl trapping functional group is in tho omega-, omega-1 or other isomeric position within the fatty acyl chains, wherein each fatty acyl chain may have from 3 to 26 carbons, from one to five nitrogen functional groups and from one to 24 hydroxyl groups; o. synthetic polysaccharides consisting partly or entirely of aminosugars bound by beta-1,2, bcta-1,3, beta-1,4 and/or bcta- 1,6 linkages; f. mixed polysaccharide polymeric derivatives wherin primary amine, aminoalkyl (one to ten carbons per alkyl group), amino- hydroxyalkyl (one to ten carbons per alkyl group and one to ten hydroxyl groups per alkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ten carbons per alkyl group) , aminoalkyl- guanidinyl (onε to ten carbons per alkyl group), guanidine, aminobenzene and/or aminoalkylbenzenc (one to ten carbons per alkyl group) functional groups are covalently attached to matrices such as cpi-chlorohydrin copolymers of cellulose or chitin and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups; and g. non-polysaccharide polymeric derivatives wherein primary amine, aminoalkyl (one to ten carbons per alkyl group) , aminohy- droxyalkyl (one to ton carbons per alkyl group and one to ton hydroxyl groups per alkyl group), aminoguanidine, aminoguani- dinylalkyl (one to ton carbons per alkyl group), aminoalkyl- guanidinyl (one to ten carbons per alkyl group), guanidine, aminobenzene and/or aminoalkylbenzcne (one to ten carbons per alkyl group) functional groups are covalently attached to a synthetic non-digestible polymer selected from the group consisting of polystyrene, styrenε-divinylbenzenε copolymer, polyvinyl alcohol and crosslinked derivatives thereof, and wherein hydrocarbon spacer groups may include alkene as well as alkyl groups, in a dosage range of from one gram/day to 40 grams/day, in a microfibrillated form or microcrystalline form having enhanced surface area, increased porosity, increased water retention capacity and enhanced chemical accessibility, and in association with a pharmaceutically acceptable carrier thereof. 30. The composition of Claim 28 characterized in that at least one co-agent is selected from the group consisting of anti¬ oxidants and free radical trapping compounds, chemicals having indirect antioxidant properties, suspending reagents, vitamins and dferivatives thereof, chemical conjugating agents which facilitate kidney drug elimination, metabolites at risk of depletion, and sulfhydryl containing chemicals.

Inventors: SHAPIRO HOWARD K, SHAPIRO, HOWARD, K.
Applicants: SHAPIRO HOWARD K, SHAPIRO, HOWARD, K.
Application year: 1993
Main classification: A61K31
IPC codes: A61K31